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ABSTRACT   
 
 
METABOLIC REPROGRAMMING OF HUMAN LUNG CANCER CELLS AND EX 
VIVO TISSUES REVEALED BY UHR-FTMS ANALYSIS OF SMALL AMINO 
AND CARBOXYL METABOLITES 
 
Studies were carried out to understand how human lung cancer cells and human 
ex vivo lung cancer tissues that are metabolically reprogramed compared with 
analogous non-cancer cells or non-cancer tissues. A Stable isotope resolved 
metabolomics (SIRM) approach was used to fulfill this aim by employing 13C, 2H 
or 15N labeled metabolic precursors like 13C6-Glc, 13C2-Gly, 2H2-Gly, 2H3-Ser, 
13C5, 15N2-Gln to trace the flow of the labeled atoms into the down stream 
metabolic network. NMR and mass spectrometry are two major analytical tools 
utilized in these types of metabolic studies. Regarding mass spectrometry, to be 
able to resolve neutron mass difference between C, H, N in complex metabolite 
pools and obtain reliable isotopologue data for each metabolite in trace sample 
size from human, an ultra-high resolution Fourier transform mass spectrometry 
(UHR-FTMS) with highly sensitive electro-spray is required. However, direct 
infusion UHR-FTMS analysis of small polar metabolites has been difficult to 
achieve.  
 
In this dissertation, analytical derivatization methods were developed for small 
amino and carboxyl metabolites to make them quantitatively analyzable by UHR-
FTMS. These methods were employed on both human lung cell lines and 
tissues resected from surgery. Metabolic pathways like glycolysis, the Krebs 
Cycle, one-carbon metabolism, nucleotide synthesis and protein turnover were
examined and profiled from the analysis of amino and carboxyl metabolites such 
as amino acids.  
 
Relevant to this analysis, Ala can be de novo synthesized from pyruvate, which is 
the product of glycolysis. Asp and Glu can be synthesized from the Krebs Cycle 
intermediates oxaloacetic acid and α-ketoglutarate. Gly and Serine exchange is 
part of the one-carbon metabolism and they serve as the precursors of the 
nucleotide synthesis. As the amino acids are the building blocks of protein, the 
amino acids turnover in protein can also reveal the protein turnover. 
 
  
The activities of glycolysis and the Krebs Cycle differ significantly between 
different lung cell lines. However, by comparing the lung cancer tissue and non-
cancer tissue generated from the same patient, it is clear that the glycolysis 
activity is increased in cancer tissue since the de novo synthesized alanine is 
increased. The different labeling patterns of aspartate indicate enhanced activity 
of pyruvate carboxylase in cancer tissues. In addition, the Gly and Ser exchange 
activity seems more active in cancer tissues. Furthermore, we traced the labeling 
flow to nucleotide synthesis via the labeled atoms from glycine or serine, and 
found preferred precursor source for nucleotide synthesis. The tissues were also 
treated with different drugs to investigate the drug effect on cancer or non-cancer 
tissues. The maintained 3D structure and micro-environment of tissues present a 
more convincing result than the cell experiments.  
 
Finally, immortalized human bronchial epithelial BEAS-2B cells are believed to 
be transforming with chronic arsenic exposure, which were examined with time 
course experiments to study how the arsenic alters the metabolism chronically in 
BEAS-2B cells. The effects of arsenic exposure and various culture conditions on 
the metabolism of BEAS-2B cells were further studied. 
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Chapter 1 : Introduction 
 
1.1 introduction to lung cancer 
Lung cancer is the leading cancer killer among men and woman in the United 
States. It is estimated that new lung and bronchus cancer cases will be 224,390 
in 2016, which will account for 13.3% of all new cancer cases, and the estimated 
number of deaths from lung cancer in 2016 will be 158,080, which would 
represent 26.5% of all cancer deaths (1). Kentucky holds the highest lung cancer 
incidence and death rate, which is not surprising giving the economic and cultural 
history as a leading tobacco-producing state and ranking first in the percentage 
of adult-smokers. In the general US population, lung cancer is more common in 
men than women, especially African American men (1). 
Although the incidence rates of lung cancer are slightly decreasing in North 
America, Europe and Australia since 1992, the rates are still increasing in Asia 
and Africa. And it should be noted that the slight decrease of lung cancer 
incidence is largely due to the change of the smoking prevalence; there is very 
limited improvement of the lung cancer diagnosis and management in past 
decades. The 5-year survival rate for lung cancer is only 17.7% according to the 
reported data 2006-2012, which is much lower than other common cancer types 
(compared with prostate cancer at 99%; breast cancer at 90%; colorectal cancer 
at 65%). However, if the cancer is localized and is diagnosed and treated early, 
the expected 5-year survival rate is much higher at 55.2%. And if the cancer is 
caught at stage 0, the estimated 5-year survival rate improves to 70-80% (1). 
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Like many other diseases, the seeds of lung cancer are sown early, and the 
clinical symptoms are delayed for many years. Since at early stages it’s often 
asymptomatic, most of the patients are diagnosed later with advanced or 
incurable cancer. Therefore, there is a crucial and urgent need to develop a 
diagnostic tool for early detection of lung cancer.  
 
1.2 Current lung cancer treatment methods 
There are two broad classifications of lung cancer: small cell (SCLC) (ca. 15% of 
cases) and non-small cell lung cancer (NSCLC) (ca. 85% of cases). NSCLC is 
further divided into subtypes that are treated differently including 
adenocarcinoma, squamous cell carcinoma, large cell and neuroendocrine lung 
cancer   
For NSCLC, the treatment methods are highly dependent on the stage of the 
cancer. According to the TNM system, the stages of lung cancer were 
determined based on the tumor size (T), whether the cancer has spread into 
lymph nodes (N), or whether the cancer has metastasized into other parts of the 
body, such as liver, brain or bones (M) (2, 3). Stage 0 NSCLC is often known as 
carcinoma in situ, with tiny size cancer which has not spread into deeper lung 
tissues or other tissues. Stage I NSCLC is defined as the cancer presents inside 
of lung but not affects the lymph nodes yet. In Stage II NSCLC, the cancer may 
spread into the chest wall or nearby lymph nodes. When cancer continuously 
spreads into lymph nodes or nearby organs, it becomes stage III. And when 
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cancer is metastasized throughout the body affecting liver, brain or bones, stage 
IV NSCLC is reached (4). 
For early stages, when the tumor is localized, surgery is usually the best option, 
sometimes followed by chemotherapy or radiation therapy. Other methods like 
photodynamic therapy, electrocautery and laser surgery are also often used (5). 
For higher stage NSCLC, surgery is often not an option. Combination 
chemotherapy and maintenance therapy are usually used. Small-molecules such 
as erlotinib and crizotinib are used to treat adenocarcinoma NSCLC in target 
therapy. They act as tyrosine kinase inhibitor, targeting on the epidermal growth 
factor receptor (EGFR), and as an anaplastic lymphoma kinase (ALK) inhibitor 
respectively (6). External radiation therapy is also used to relieve pain and 
improve life quality. In addition, late stage patients are also often involved in 
clinical trial of new drugs (1).   
For SCLC, the stages are defined as limited-stage, in which the cancer still 
remains in lung or has limited spread to area between the lungs or to the lymph 
nodes above the collarbone; and extensive-stage, in which the cancer has 
spread to other part of the body. Treatment involved in SCLC often includes the 
combination of chemotherapy and radiation therapy (7). 
Nevertheless, most current treatments are only palliative care and do not cure 
the lung cancer for most patients. Overall this is a dismal outcome, and therefore 
greatly improved methods are needed to understand the basic biochemical 
pathology, and for early detection and improved treatments. 
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1.3 Studying cancer from a metabolic view 
Is cancer a genetic or metabolic disease? This has been a controversial question 
for decades in the medical field. Back in the 1920s, Otto Warburg proposed that 
the cancer cells consume more than 200-fold glucose than normal cells, and 
undergo a much accelerated glycolysis even in normoxic conditions (Warburg 
effect) (8, 9). Before the 1970s, most cancer researchers tried to study cancer 
from a metabolic view and many of the anti-cancer drugs discovered in 1950s 
and 1960s were called “antimetabolites” (10). Later the viral origin of cancer 
became popular for a while. It was reported that 15% of human cancers was 
driven by viruses (11, 12). After Otto Warburg’s death and with the discovery of 
oncogenes in 1970s, many researchers shifted their study of cancer to a genetic 
view rather than a metabolic view. It is generally believed that cancer 
development involves mutations of protooncogenes and tumor suppressor genes 
(13). Mutations in KRAS and overexpression of MYC have been shown to occur 
frequently in cancer cells, and there are many other well-characterized oncogenic 
driver gene somatic mutations, including EGFR and STK11 in lung 
adenocarcinomas, PI3K in SCC, and TP53 in the majority of cancers (14-18). 
Mutations in the NF-κB signaling pathway could also be oncogenic and result in 
angiogenesis and metastasis (19-23), and mutations in BRCA1,2 are associated 
with a very high risk for breast cancer (24, 25). Since 1971, more than $200 
billion has been spent on cancer research worldwide. Despite all the exciting 
discoveries of genetic mutations of cancer, the overall decrease of death rates of 
cancer is much less compared to other diseases such as stroke and heart 
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disease, where the death rates have dropped by 70% (26, 27). This is particularly 
serious with lung cancer. The mortality of lung cancer in 2013 stayed almost the 
same compare to the year of 1975 (1). The short answer for why the cancer 
study progress is so slow is that cancer is a very complex, expedient set of 
diseases. Tracing back the history of cancer risk study, it seems almost any 
provocative agent in the environment can potentially cause cancer after chronic 
exposure (28, 29). Indeed, there are currently at least 1000 genes in humans 
associated with cancer development, and typically more than a mutation in more 
than one of these genes is needed to develop cancer (10). That is to say, millions 
of cancer genotypes are yet to be elucidated. This makes the drug design based 
on genetic fingerprints of tumors a huge challenge. Moreover, most of the 
cancers are of somatic origin which arise from a wide range of environmental 
insults, like smoking, which may not be detected via regular genetic screening. 
Over the last decade, some cancer researchers have gradually shifted their 
attention back to metabolism. Regardless of the numerous genetic fingerprints of 
cancer, it is well known that many cancers have a limited repertoire of metabolic 
reprogramming that is consistent with proliferation, survival and metastasis (8, 
10, 30-38) such as elevated aerobic glycolysis (the Warburg effect). Interesting 
experiments conducted by Thomas N. Seyfried suggest that some cancers might 
have originated from mitochondrial defects. (30) Cytoplasmic nuclear transfer 
experiments were conducted and the results showed that when enucleated 
cancer cells were infused with nucleated non-cancer cells, the tumorigenicity was 
found in the cybrids, whereas when enucleated normal cells were infused with 
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nucleated cancer cells, the tumorigenicity was suppressed. Although some rare 
familial cancers are attributable to mutations in mitochondrial enzymes like 
fumarate hydratase and succinate dehydrogenase (39-42), these findings still 
questioned the dominant role of the genetic origin of cancer to a certain extent. 
This indicates the importance of metabolism in cancer and why the cancer-
specific reprogramming needs to be better understood.  
A universal trait of cancer cells is uncontrolled growth. This process requires 
additional energy and metabolite precursors to support the anabolic requirements 
for proliferation. Profound metabolic changes must occur in cancer cells to 
sustain this high demand. (43) Aerobic glycolysis is well known being accelerated 
in almost all cancer types, but the energy generated from glycolysis itself is 
limited and may not be sufficient to support the massive growth of the cancer 
cells. Anabolic pathways related to all aspects of cellular functioning, including 
lipids, amino acids, nucleotides, proteins biosynthesis must all be elevated in 
cancer cells for proliferating demands. In the past, it was thought that 
mitochondria were “dysfunctional” in cancer cells. However recent reports 
showed accelerated Krebs Cycle activity in cancer cells and tissues (34, 38), 
which actually makes sense given that many intermediate metabolites in the 
Krebs Cycle like oxaloacetic acid (OAA), α-ketoglutarate are important 
precursors for the biosynthesis of amino acids, nucleotides and proteins, which 
are all required for cancer cell proliferation. Therefore, a global systematic study 
of metabolism is crucial in cancer research. 
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1.4 Stable Isotope Resolved Metabolomics (SIRM) as an essential approach 
for studying cancer metabolism. 
Unlike the substrates in other “omics”, the chemical nature of the metabolites is 
far more diverse. Also, the concentration range is large and highly variable for 
different metabolites across different tissues and organs. Thus, a systems 
metabolomic analysis has unprecedented technical challenges among the 
“omics” (44). High resolution, high sensitivity analytical tools are needed, that can 
provide structural identity as well as accurate quantification. The two major 
analytical tools that satisfy these criteria are mass spectrometry and NMR. The 
very large datasets that are acquired also makes demands on data reduction and 
interpretation which require advanced bioinformatics and multivariate statistical 
methods.    
However, the metabolic information yielded from only the concentration or total 
amount obtained by profiling is of limited use, as a single metabolite often 
participates in more than one pathway, and many pathways could intersect with 
each other to form a complex network (as shown in Figure 1.1) (44). For 
example, Glu in a living system (cell) can come from culture medium, be 
synthesized from Gln through glutaminolysis, or be de novo synthesized from α-
ketoglurarate, which can be derived from glucose originally through glycolysis 
and the Krebs cycle. On the other hand, Glu is also the bio-precursor for GSH, 
protein, or other amino acids synthesis. In this case, in order to identify the 
precursor-product relationships, it is necessary to “label” the individual atoms in 
one metabolite so that their fates can be traced through metabolic pathways. 
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Radioisotopes were used to achieve this in the past (45-48). Nowadays, stable 
isotopes are increasingly used, since they are biocompatible, nonhazardous, and 
the stable isotopes such as 13C, 2H and 15N can substitute for their lighter 
isotopes (12C, 1H, 14N) in structures of metabolites without altering their 
biochemistry, yet are easily distinguished from their natural isotopic signatures by 
NMR or by MS (37, 44, 49, 50). No other analytical technique meets this 
fundamental need so readily. 
 
Figure 1.1 Metabolite often participates in more than one pathway.  
With stable isotope labeling of the precursor glucose, de novo synthesized 13C-
lactate or 13C-Glu could be distinguished from lactate and Glu coming from other 
unlabeled source (medium or protein turnover).   
 
Stable Isotope Resolved Metabolomics (SIRM) enables the global metabolic 
profiling by atom-resolved tracking of metabolites within cells, tissue or whole 
organisms (44). The biological system is usually provided with a metabolic 
precursor (e.g. nutrient) source which is enriched at one or more atoms with a 
stable isotope (such as 13C, 15N or 2H), and the metabolites are analyzed by 
NMR and MS after treatment at different times. By determining the specific 
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isotopologue distribution in the various product metabolites, it is possible to 
reconstruct the biosynthetic pathway, and estimate fluxes via models(43). 
Using two different stable isotope tracers to label different metabolite precursors 
simultaneously makes it possible to profile different pathways at the same time or 
simultaneously track more than one atom from a precursor in a single 
experiment, thereby providing more information about how pathways and atoms 
relate to each other. For example, using 13C6-Glucose and 2H2-Glycine 
simultaneously enables tracing glycolysis, the Krebs Cycle, PPP pathway, 
nucleotide synthesis and one carbon metabolism pathway including Ser and Gly 
exchange. As both NMR and MS can distinguish these isotopes, multiplexed 
experiments are possible.   
As mentioned before, MS is one of the important analytical tools for these types 
of metabolic studies. As 13C, 15N and 2H differ from the most abundant isotopes 
only by a single neutron nucleon, which has a nominal mass of 1, a molecule 
containing either one 13C or one 15N atom often cannot be distinguished by low or 
intermediate or lower resolution mass spectrometry. However, they can be 
distinguished using sufficiently high mass resolution, as afforded by only the top-
end models, which will be termed Ultra-high resolution Fourier Transform 
mass spectrometers (UHR-FTMS) (Figure 1.2). In addition to very high 
resolution, the UHR-FTMS is also capable of high mass accuracy (<0.2 ppm 
RMS error with external calibration) for molecular formula information, and with a 
detection sensitivity requiring only femtomole or lower amounts of each analyte 
(44).  
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Figure 1.2 FTMS can resolve the small mass difference of neutrons.  
UHR-FTMS spectrum shows glutamate simultaneously labeled with 13C, 15N and 
2H in a cancer cell extract (black line). The small m/z difference is distinguishable 
using only the highest resolution mass spectrometer models.  
 
Compared to more widely used methods used to study metabolomics, such as 
conventional resolution GCMS and LCMS (51), the advantages of UHR-FTMS 
coupled with direct infusion are evident as follows. For GCMS, only volatile 
chemicals can be analyzed directly, which requires derivatization to render most 
metabolites sufficiently volatile. Further, GC is hard to couple to UHR-FTMS 
since the high resolution in MS often sacrifices the resolution of chromatography 
because of the low speed of detection compared with the chromatographic peak 
widths. LCMS has the advantage over GC-MS in that a much wider range of 
analytes can potentially be measured. However, the rapidly changing 
concentrations presented to the MS from LC or GC cannot provide isotopologue 
data as quantitatively as continuous infusion, because the latter can average 
 11  
signals over many minutes to obtain far greater signal-to-noise spectra. Among 
the direct infusion methods, we have chosen to use nano-ESI because of its high 
sensitivity and it is especially suitable for small size sample introduction (less 
than 20 µl), which is crucial for human cell or tissue samples that are often of 
very limited material mass. For these reasons, UHR-FTMS coupled with nano-
ESI is the optimal choice for mass spectrometry based SIRM studies. 
 
1.5 Rationale of this study 
The overall aim of this research was to determine the metabolic reprogramming 
that occur in cultured human lung cancer cells or human ex vivo lung cancer 
tissues in comparison to non-cancer cells or non-cancer tissues. In order to 
increase the coverage of metabolites that can be analyzed, it as necessary to 
develop methods for accurate determination of amino and carboxyl-containing 
metabolites and their isotopologues in multiplexed SIRM experiments using 
UHR-FTMS with direct infusion. These quantitative methods were applied to 
determine how to derive detailed pathway information of lung cancer cells and 
tissues, including both polar metabolites and proteins. 
 
 
 
 
 
 
 12  
  
Chapter 2 : Analysis of amino and carboxylate containing metabolites by 
Ultra-High Resolution FTMS 
 
2.1 Importance of amino and carboxylate containing metabolites. 
Amino and carboxyl are two of the most common functional groups present in 
metabolites. Most important metabolites involved in most central pathways fall 
into these classes, including amino acids, polyamines, GSH, GSSH, all of the 
metabolites in the Krebs cycle, the glycolysis products pyruvate and lactate, 
neurotransmitter molecules like N-acetylaspartate, and the ubiquitous methyl 
group transfer molecule S-adenosyl methionine (SAMe), just to name a few 
examples. Analysis of many of these metabolites is crucially important for the 
systematic profiling of central metabolism. 
Among these, amino acids have crucial roles in many of the pathways mentioned 
above, including both anabolic and catabolic metabolism, and as free and in 
macromolecular forms.   Not only are they the building blocks of proteins, they 
can also be oxidized to provide metabolic energy (52). The non-essential amino 
acids Ala and Glu can be biosynthesized from glucose and other nutrients, and 
play important roles in nitrogen metabolism via transamination, along with Arg, 
Orn and citrulline in the urea cycle. Ser, Gly, Gln and Asp are precursors in 
nucleotide synthesis, providing both carbon (from Asp and Gly) and nitrogen 
(from Gln, Asp, and Gly) to the nucleobases (53). Gln is also the nitrogen donor 
in the synthesis of amino sugars (54).  Arg, Orn and Met are also precursors of 
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polyamines, which play important roles in stress tolerance and nucleic acid 
function (55, 56). 
It is therefore very important to be able to quantify amino acids in cells, measure 
changes in concentrations and determine their transformation pathways.   For the 
latter, stable isotope tracers make it possible to follow the fate of individual atoms 
from precursor molecules through metabolic transformations (57, 58). 
A large number of analytical methods have been reported for the quantification 
analysis of amino acids in biological systems. N-tert-butyldimethylsilyl-N-
methyltrifluoroacetamide (MTBSTFA), introduced by Fan et al. in 1986 for GCMS 
analysis of amino acids, has been one of the most widely used silylation reagents 
for quantification analysis of amino acids (49, 59, 60). In 1991, Husek reported 
the derivatization of amino acids with ethyl chloroformate which enabled the 
analysis of amino acids by GCMS within five minutes (61). Researchers later 
modified the ethyl chloroformate (ECF) derivatization method and applied it to a 
variety of biological samples including foodstuffs, plant and urine samples (62, 
63). 9-Fluorenylmethyl-chloroformate (Fmoc-Cl) coupled with HPLC or 
fluorescence detection was reported for analysis of amino acids in fruit juice and 
hydrolyzed peptides (64). Structurally related reagents including isobutyl 
chloroformate, methyl chloroformate, pentafluorobenzyl chloroformate have also 
used for amino acids analysis (65-67), although none of these were intended for 
use with SIRM. 
As described above, measurement of the total amount of metabolites by most of 
the above methods does not provide enough pathway-specific information as a 
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single metabolite often participates in more than one pathway, and a steady state 
level does not determine the relative rates of production and utilization. We 
therefore use SIRM for the analytical detection of metabolite flux changes in lung 
cancer cells and tissues. 
 
2.2 Advantages and limitations of direct infusion UHR-FTMS analysis of 
small polar metabolites: 
Nano-ESI-UHR-FTMS has been successfully applied to analyze lipids, 
nucleotides, and other metabolites in SIRM studies (37, 44, 68), and the 
advantages of UHR-FTMS were explained in Chapter 1. However, it has been 
difficult to detect low m/z and/or polar metabolites such as amino acids and 
polyamines in crude cell extracts by this method, because of the electrospray ion 
suppression and resulting instability of nano-ESI caused by the high salt content 
in biological extracts, which also increases sample consumption due to lowered 
sensitivity in valid spectra, which in turn compromises sample throughput due to 
re-analyses, and overall interferes with quantitative data analysis. Furthermore, 
all current UHR-FTMS models are optimized for analytes with m/z >150, 
compromising performance for smaller m/z metabolites. These problems are not 
only cumulative, but further exacerbated by the need for analyzing a large 
number, typically thousands of labeled isotopologues present at very low 
abundance in SIRM experiments, even for abundant metabolites whose 
monoisotopic species are readily detected by UHR-FTMS.  Lastly, the 
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biochemical lability of some metabolites makes them impractical to quantify with 
confidence.  
Therefore, there is a need to develop a suitable derivatization method for these 
small metabolites, specialized for nano-ESI-UHR-FTMS analysis.   
 
2.3 Amino and carboxyl metabolites analysis in native form 
2.3.1 Background 
Analysis of metabolites in their native form is very important to attempt because it 
can avoid the problems of contamination or sample degradation when using 
derivatization reagents, with fewer sample preparation steps, thus providing more 
straightforward and precise information. It also gives a baseline for comparison of 
derivatization methods, if they are needed. Since amino acids contain both amino 
and carboxyl functional groups and play important roles in several central 
metabolic pathways, they were mainly used as target metabolites for methods 
development. A major improvement then would be to effectively desalt the 
samples prior to injection into the UHR-FTMS. 
As an example of direct infusion of metabolites in their native form, our group has 
recently developed a rapid method (69) to analyze nucleotides using C18 “ziptips” 
(Z-Tip) and the ion-pairing reagents hexylamine to clean up the cell extract, 
thereby obtaining a stable spray in direct infusion nano-ESI with outstanding 
quantification of the target compounds. The C18 Z-Tip is a pipette tip with a small 
amount of chromatography media fixed at its end. It is designed for concentrating 
and purifying protein and peptide samples by analyte binding followed by sample 
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elution (64). Use of an ion-pairing reagent in conjunction with C18 tips proved to 
be the useful key, the structure of which generally contains an aliphatic chain at 
one end that helps it bind to the C18 tip, and a hydrophilic group at the other end 
to interact with the polar metabolites.  Analytes with different functional groups 
may require different ion-pair reagents. Based on the C18 and ion pair idea, for 
amino metabolites, I chose to investigate ion-pairing with perfluorocarboxylic 
acids (PFAs), which are routinely reported as ion-pair reagents in liquid 
chromatography for separating amino acids (70),  to investigate their 
compatibility with C18 tip and their ability to extract amino acids from sample pool; 
and thus try to obtain a stable ion spray for amino acids analysis in cell crude 
polar extracts. 
2.3.2 Methods 
Materials:  
Amino acid standards physiological acidic and neutrals (A6407) and amino acid 
standards physiological basics (A6282) along with perfluorocarboxylic acids were 
purchased from Sigma Aldrich (St.Louis, MO). Methanol was obtained from 
Burdick and Jackson (Morristown, NJ). C18 tips were purchased from Millipore 
(Billerica, MA).  
Cell culture: 
Familial renal carcinoma cell UOK262 (in which both alleles of fumarate 
hydratase are defective) and the wild type (wt) UOK262 cells (which are 
introduced with gene vector to reactivate their fumarate hydratase) were obtained 
from Dr. Linehan’s laboratory at NCI (Urologic Branch). The cells were cultured in 
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10cm plates with DMEM medium containing 25 mM 10% fetal bovine serum, 100 
U penicillin, 100 µg/ml streptomycin, 4mM unlabeled Gln, until 80% confluent 
(42). 
Metabolites extraction: 
At the time of harvest, media was removed and collected using transfer pipette. 
The cell plates were washed with ice cold PBS for 3 times and PBS was 
removed as much as possible by vacuum aspiration after the last time wash. 
Then the cells were quenched using 1ml acetonitrile stored at -20°C, followed by 
750μl nanopure water added. The cells were harvested by being scraped off from 
the plate. The whole process was repeated, following 1ml CHCl3 was added to 
extract polar, non-polar, protein fractions in CH3CN: H2O: CHCl3 2:1.5:1 (71). The 
polar extract fraction was then aliquot and lyophilized for downstream analysis. 
Sample processing: 
The C18 tip was first conditioned with MeOH then 0.5 mM aqueous PFA solution 
by aspiration. Amino acids standard samples and lyophilized cell polar extracts 
were first dissolved in the aqueous PFA solution and then adsorbed onto the 
MeOH-conditioned C18 tips by consecutive aspirations. The amino acids were 
then eluted from the tips by 50 μl MeOH. The combined elution fractions were 
dried with vacufuge and re-dissolved in MeOH, and analyzed directly with a 7T 
LTQ-FT ™ (Thermo) coupled with direct infusion nano-ESI source (Triversa 
Nanomate™ from Advion). Different PFAs were tested and compared, including 
perfluorobutynoic acid (PFB), perfluoropentanoic acid (PFP), perfluorohexanoic 
acid (PFhexa), perfluoroheptanoic acid (PFH), perfluorooctanoic acid (PFO), and 
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perfluorononanoic acid (PFN), among which PFhexa, PFH, PFO, PFN show 
better efficiency. The PFB and PFP showed lower signal response apparently 
due to their shorter aliphatic chain resulting weaker binding to C18 tip. The tips 
were conditioned with 50 μl MeOH and PFA water solutions (5mM) by aspirating 
the C18 tip on the pipette quickly 12 times. Then the sample was loaded (amino 
acids) to C18 tip through the aspirating pipette with the C18 tip in 30 μl working 
sample (amino acids in PFA water solution) slowly for 8 times. Then they were 
eluted with 50uL MeOH by the aspirating pipette 12 times quickly. The above 
was repeated for 4 cycles. In the last cycle, sample was eluted in 3 pools of 
MeOH consecutively. Finally all elutes were combined and dried by vacufuge and 
then re-dissolved in 50μl MeOH for FTMS injection.  
Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) 
analysis:  
The Thermo LTQ-FT instrument was calibrated according to manufacturer 
protocols and tuned using the (Ala+H)+ peak (theoretical m/z=90.05495). Data 
were acquired in positive mode. The Triversa Nanomate was operated at 1.5kV 
and 0.5 psi head pressure. The maximum ion time for the automatic gain control 
AGC was set to 1000ms (68). Five transients were added to produce a stored 
spectrum. Spectra were acquired for at least 5 min.  
2.3.3 Results and Discussion 
Test on amino acids standards: 
Amino acids standards A6407 and A6282 are mixed to make all amino acid 
concentrations be 15 µM. The results are shown in Figure 2.1. After being 
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processed by PFhexa, the spray was still stable. All the amino acids in the 
standard mixture could be detected except for Gly. 
 
Figure 2.1 FTMS spectrum of PFhexa processed amino acids mixture using 
C18 tip. 
x-axis is the m/z value of metabolites whereas y-axis represents the UHR-FTMS 
signal intensity. Most of the amino acids in the standard mixture could be 
detected by UHR-FTMS using this method. But the mass spectral signal 
response for smaller amino acids are poor (such as Ala and Val).  
Test on unlabeled UOK262 crude cell polar extract: 
I then did a test on cell polar extract using PFhexa, to see if I could get stable 
nano-electro spray of cell crude polar extract after PFA processing.  
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Figure 2.2 FTMS spectrum of PFhexa processed UOK262 cell polar extract 
using C18 tip. 
x-axis is the m/z value of metabolites whereas y-axis represents the UHR-FTMS 
signal intensity. Stable electro-spray could be obtained for the cell polar extract 
after processing with C18 tips thus. Several important amino-group containing 
metabolites could be detected with UHR-FTMS with decent signals. 
As shown in Figure 2.2, after processed with PFhexa, the spray of the cell polar 
extract was much more stable than without processing. Most amino acids could 
be detected, which may provide a large amount of information mappable to 
related metabolic pathways. 
Figure 2.3 is a summarization of the 0.5mM PFA processed amino acid 
standards (15 μM). The UHR-FTMS signal from original spectra was normalized 
with an internal standard 1 μM 9-aminoacridin (9-AA). The amino acids are 
shown in an increasing m/z order. 
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Figure 2.3 UHR-FTMS signals of PFA processed amino acids normalized 
with internal standard in a m/z increasing order. 
The intensities of analytes were normalized with internal standard 9-aminoacridin 
(9-AA). For the small analytes, the UHR-FTMS signals were usually low. 
 
The ion suppression effect caused by high content of salt is partly mitigated by 
ion-pairing the amino group containing metabolites with perfluorocarboxylic acids 
and using the C18 tips to desalt the solution. However, as stated earlier, the UHR-
FTMS is designed to detect analytes with m/z >150, so that smaller metabolites 
are hard to detect; unfortunately, these such as Gly and Ala, are crucially 
important since they are involved in many critical metabolic pathways like one-
carbon metabolism, nucleotide synthesis, and nitrogen metabolism. In addition 
for some metabolites, their concentration in biological samples could be very low 
or their response factor in UHR-FTMS may not be sufficient to give reliable 
labeling information. Furthermore, the labile nature of some metabolites (e.g. 
oxaloacetate) makes them impractical to detect accurately. Although this method 
is straightforward and effective for many compounds, there still remains a need 
for us to develop a suitable derivatization method for these critical small 
metabolites for UHR-FTMS coupled with nano-ESI analysis. 
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2.4 Amino and carboxyl metabolite analysis using derivatization 
approaches. 
2.4.1 Ethyl chloroformate (ECF) derivatization 
2.4.1.1 Rationale: 
Ethyl chloroformate has been widely reported for derivatization reagent of amino 
or carboxyl compounds for example GCMS analysis (61-63, 72-75). In this study 
this method has been modified and optimized for amino and carboxylate-
containing metabolites to become suitable for direct infusion coupled with UHR-
FTMS analysis, and tailored to very small biospecimen sizes, such as one-time 
lung cancer patient tissue extract. In this section, amino acids analysis by ECF 
derivatization was  studied. The reaction mechanism of ECF derivatization of 
amino acids is shown in Figure 2.4 (62). Other amino or carboxyl metabolites 
like S-adenosyl methionine, N-acetylaspartate, GSH and GSSG derivatization by 
ECF were also studied.  
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Figure 2.4 Reaction mechanism of ECF derivatization of amino acids 
2.4.1.2 Methods 
Reagents 
All amino acids standards were purchased from Sigma Aldrich as acidic and 
neutral (A6407) and basic (A6282) mixtures. Glutamine, GSH, GSSG, S-
adenosyl methionine, N-acetylaspartate and ethyl chloroformate (ECF), ethanol, 
pyridine and chloroform are also purchased from Sigma Aldrich. The uniformly 
15N-labeled amino acids mixture was purchased from Cambridge Isotope 
Laboratories (Cambridge, MA). 
Preparation of amino acids standards: 
Amino acids mixtures A6407 and A6282 were freshly combined in equal amounts 
before experiments. Aqueous glutamine solution was also added into the amino 
acid mixture just prior to experiments due to its liability. In the final solution, the 
concentration of each amino acid was 0.556 mM except cystine, which was half 
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of the concentration as the others. This stock was then serially diluted to make 
amino acids concentration at: 0.278 mM, 0.111 mM, 0.056 mM, 0.028 mM, 0.011 
mM, 0.0056 mM, 0.0011 mM. 
Cell culture: 
Human lung adenocarcinoma PC-9 cells were grown on 10 cm cell culture plates 
in DMEM medium containing 10% fetal bovine serum (FBS), 50 U mL-1 penicillin, 
50 µg mL-1 streptomycin (Fisher Scientific, Waltham, MA), 0.2% unlabeled 
glucose till 80% confluent as described previously (35).  
Metabolites extraction: 
At the time of harvest, media was removed and collected using transfer pipette. 
The cell plates were washed with ice cold PBS for 3 times and PBS was 
removed as much as possible by vacuum aspiration after the last time wash. 
Then the cells are quenched using 1ml acetonitrile stored at -20°C, following by 
the addition of 750 μL nanopure water. The cells were harvested by being 
scraped off from the plate. The whole process was repeated, following by adding 
1 mL CHCl3 to extract polar, non-polar, protein fractions in CH3CN: H2O: CHCl3 
2:1.5:1 as described previously (71). Then 1/16 of the aqueous phase containing 
polar extracts was aliquoted and freeze-dried for ECF derivatization. 
ECF derivatization: 
For the amino acid standard, 9 µL of the prepared amino acid standard mixture 
was used. H2O/Ethanol/Pyridine (6:3:1) mixture (100 µL) was added to 1/16 of 
cell polar extract from a 10 cm plate, followed by 5 µL ECF agent (62). The 
mixture was allowed to react for 30 s during which it was vortexed continuously. 
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100 µL chloroform was then added to extract the products then shaken, with the 
CHCl3 removed.  This was followed by 10 µL 7 M NaOH to adjust the aqueous 
layer to pH 9-10, after which a further 5 µL of ECF was added and allowed react 
with vortexing again for 30 s. The solution was extracted a second time with 100 
µL chloroform which was pooled with the 1st extract. The chloroform extract was 
diluted 100-fold for the amino acid standards and 10-fold for cell or tissue 
samples with 90% acetonitrile plus 20 µM NaCl to convert the ions to the sodium 
adduct. The samples were then directly injected into the UHR-FTMS using nano-
ESI.     
Mass spectrometry and peak assignments 
UHR-FTMS was carried out using the Tribrid Fusion Orbitrap interfaced with an 
Advion Triversa Nanomate Thermo Scientific. The Triversa Nanomate was 
operated at 1.5 kV and 0.5 psi head pressure for positive mode. The maximum 
ion time for the automatic gain control AGC was set to 100 ms as described in 
(68). Five transients were added to produce a stored spectrum. Each spectrum 
was acquired for >5 min.  
All 12C, 13C and D isotopologue peaks were assigned using “PREMISE” 
(PRecaculated Exact Mass Isotopologue Search Engine) (37) based on their 
accurate m/z values and the natural abundance distribution of each isotopologue 
was stripped using the method developed by Dr. Hunter NB. Moseley (76). 
2.4.1.3 Results and Discussion: 
Analysis of amino acids standards: 
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The ECF derivatization method was first evaluated using the amino acids mixture 
(Table 1). As previously discussed, these polar metabolites are crucial in cellular 
function but are difficult to detect directly by direct infusion UHR-FTMS in crude 
cell polar extracts due to high ion suppression effect or low molecular weight.  
The 15N labeled amino acids were spiked in as internal standards for 
quantification. Since the 15N labeled amino acids were spiked before reaction 
with ECF, the ratio between the other isotopologues and the spiked 15N species 
can be used to correct for the reaction and extraction efficiency, thus making the 
other isotopologues quantifiable even in the absence of data on the absolute 
reaction efficiency of the isotopologues.  Table 1 and Figure 2.5 shows the 
UHR-FTMS analysis result, demonstrating the linearity of the response of ECF-
derivatized amino acids as a function of infused concentration (assuming amino 
acids were fully reacted with ECF). For all amino acids tested, the UHR-FTMS 
analyzed results show very good linearity, so that absolute quantification of 
amino acids by FTMS can be achieved by this method. All amino acids were 
principally observed, and therefore quantified, as sodium adducts except 
arginine, which was principally observed and quantified as the protonated form. 
With previous methods, arginine has been difficult to analyze by GCMS using 
ECF derivatization, mainly because the adduct does not readily elute from the 
GC column (61), which is avoided by direct infusion here. For histidine and 
lysine, both protonated and Na adducts were present, but the Na adducts 
dominated when the concentration was low.  
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Table 1: Linearity of response of the ECF-derivatized amino acids standard 
Amino acids N 
Linear 
range (nM) 
R2 
Ala 4 5-5000 0.995 
Arg 4 5-5000 0.999 
Asn 4 5-5000 0.997 
Asp 4 5-5000 0.998 
Cystine 4 5-1250 0.988 
Glu 4 5-5000 0.990 
Gln 4 5-5000 0.997 
Gly 4 5-5000 0.994 
His 4 5-5000 0.999 
Leu+Ile 4 5-5000 0.999 
Lys 4 5-5000 0.999 
Met 4 5-5000 0.999 
Phe 4 5-5000 1.000 
Pro 4 5-5000 0.999 
Ser 4 5-5000 0.992 
Thr 4 5-5000 0.987 
Try 4 5-5000 0.998 
Tyr 4 5-5000 1.000 
Val 4 5-5000 0.997 
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Figure 2.5 Linear response test on the ECF derivatized amino acids 
standards. 
X-axis represents the tested concentration range of each amino acid. Y-axis 
represents the relative UHR-FTMS intensity normalized with 15N-labeled amino 
acid internal standards. 
 
Analysis of amino acids in unlabeled PC9 cell polar extracts 
As discussed above, direct analysis of the cell extract without derivatization by 
direct infusion nano-ESI UHR-FTMS was unsuccessful, even after 100-fold 
dilution to reduce the ion suppression. However, after ECF derivatization 
followed by chloroform extraction, the nano-ESI spray was stable for >15 min, 
which enabled sensitive observation of isotopologue peaks for the amino acids 
and also reliable quantification of these isotopologues. Figure 2.6 shows a 
typical positive-ion mode spectrum of a PC9 cell polar extract sample derivatized 
by ECF. Low m/z amino acids such as glycine and alanine, which are hard to 
detect by direct infusion in UHR-FTMS as discussed earlier, were now easily 
detected with good peak intensities in the mid-to-upper range of the UHR-FTMS 
response.  
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Figure 2.6 Typical positive ion mode spectrum of unlabeled PC9 polar 
extract after derivatization with ECF.  
Panel A shows the larger m/z range which shows that ECF can also derivatize 
GSH and GSSG. Both GSH and GSSG showed above is the Na adduct form. 
Panel B shows the zoom-in spectrum of the amino acid range. The peak 
assignments were made using “PREMISE”(37). Most of the amino acids shown 
represent Na adduct species except Arg and His, which are protonated species. 
 
In addition to amino acids, ECF was also observed to derivatize key metabolites 
like N-acetylaspartate, S-adenosylmethionine in the same method.  
ECF derivatization of N-acetylaspartate (NAA)  
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As the second most abundant metabolite in brain, N-acetylaspartate plays 
important roles as a neuronal osmolyte in maintaining fluid balance, acetate 
donor for lipid and myelin synthesis, and the precursor of N-
acetylaspartylglutamate, which serves as a functional neural transmitter (77). 
Recent studies show that NAA might be a biomarker of cancer, in cancer cell 
studies (78, 79). Considering the amino acids-like structure of NAA, ECF 
derivatization was investigated and tested for NAA analysis. 
ECF can derivatize the two carboxyl groups on NAA in the H2O/Ethanol/Pyridine 
(6:3:1) reaction media to yield the product below: 
 
Figure 2.7 Structure of ECF derivatized NAA.  
The sodium adduct was observed as major signal with m/z 254.0999. 
 
I then searched for ECF-derivatized NAA in lung cancer patient tissue slice and 
plasma samples. The expected NAA signal at m/z 254.0999 was found in both 
cancer and non-cancer tissue slice extracts and also found in patient plasma as 
shown in Figure 2.8.  Therefore, the ECF derivatization could be used to study 
the NAA metabolic role in lung cancer. Further study still needs to be conducted 
for the quantification test of this method, however this quick study illustrates the 
easily-expandable analytical power of combining ECF-derivatization with direct 
infusion UHR-FTMS. 
O
O
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Figure 2.8 ECF derivatized NAA was found in both cancer and non-cancer 
tissue extracts of lung cancer patient UK022, and also in plasma.  
The theoretical m/z of ECF derivatized NAA is 254.09989. The assigned ECF-
NAA peak was found in both patient tissue extracts and plasma in UHR-FTMS 
spectra. 
 
ECF derivatization of S-Adenosyl methionine (SAMe):  
As a key methyl group donor, SAMe plays an important role in protein, 
phospholipids, and DNA/RNA methylation. It is also the sole donor of an 
aminopropyl group in polyamine synthesis, and in plants it is the precursor of 
ethylene, which is a fruit-ripening hormone and controls plant senescence (80). 
Figure 2.9 is the UHR-FTMS spectrum showing the detection of ECF derivatized 
SAMe standard, showing two derivatized products had been detected. 
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Figure 2.9 FTMS spectra and the structure of ECF derivatized SAMe.  
Two derivatized products were observed at m/z 571.218 and 643.239. The peak 
571.2 corresponds both -NH2, -COOH group on methionine, and one of the –
NH2 or –OH groups on adenine nucleoside were derivatized with ECF. Peak 
643.2 corresponds both -NH2, -COOH group on methionine, and two of the –NH2 
or –OH groups on adenine nucleoside were derivatized with ECF. 
 
Although SAMe as a standard provides a well-characterized ECF derivative ion 
with promising detection limits, we did not observe ions corresponding to the 
ECF-derivatized SAMe in actual cell or tissue extract samples. The reason could 
either be the concentration of SAMe is too low in cell and tissue extract or the 
SAMe is labile and decomposed during the cell or tissue extraction procedure, 
which needs further investigation. 
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2.4.2 Isobutyl chloroformate (iBuCF) derivatization  
2.4.2.1 Rationale:  
Polyamines are important amino group containing metabolites which play 
important roles in the tolerance of oxidative stress. Their synthesis and 
metabolism are involved in highly regulated pathways. Although their metabolic 
roles and molecular mechanisms are not fully understood, inhibition of polyamine 
synthesis will affect cell growth and cause a variety of diseases. Polyamines can 
function as scavengers for reactive oxygen species such as alkyl, hydroxyl and 
peroxyl radicals, and superoxide at physiological concentrations (55). There is 
research showing that spermidine can protect the proto-plant Arabidopsis sp. 
from heat stress by increasing the expression of stress response genes (56). 
Putrescine can accumulate during osmotic stress in rat, which is due to an 
increase of ornithine decarboxylase (ODC) (an enzyme involved in the first stage 
polyamine synthesis) activity, caused by a decrease in the stability of the 
regulatory enzyme of ODC (81). On the other hand, increased levels of 
polyamines are associated with increased cell growth, decreased of apoptosis, 
and a variety of cancers (82). The first report of the association between 
increased polyamine levels and cancer dates back to the 1960s, and high ODC 
activity was found in several human cancers (83). Environmental cancer 
promoters such as ultraviolet light and asbestos have also been shown to induce 
ODC activity (84, 85). In addition, increased level of ODC leads to decreased 
tumor suppressor adenomatous polyposis coli (APC), and to increased 
expression of MYC and RAS oncogene (86-89). Besides ODC, other enzymes 
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involved in polyamine synthesis such as spermidine/spermine N1-
acetyltransferase (SSAT) have been known associations with colon cancer and 
other gastrointestinal cancers (90). Therefore, the systematic detection and 
analysis of polyamine metabolism would provide valuable data for cancer 
metabolic studies. 
Many derivatization analytical methods have been developed coupled with 
GCMS or LCMS for polyamine analysis (91, 92). However, most of the 
derivatization reagents show better reaction efficiency with other amines rather 
than polyamines, and also were not intended for UHR-FTMS analyses at the 
extreme resolutions required for SIRM studies, which has special considerations 
as previously discussed.  It appears that isobutyl chloroformate seems most 
suitable for polyamines (93). Therefore, iBuCF derivatization was optimized for 
polyamine analysis by UHR-FTMS with direct infusion. 
iBuCF can react with all the –NH2 or –NH- groups on polyamines to generate 
carbamoyl groups as shown in Figure 2.10.  
 
Figure 2.10 Example reaction of iBuCF with putrescine 
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2.4.2.2 Methods   
Materials: 
Polyamine standards putrescine, cadaverine, spermine and spermidine, iBuCF, 
Na2CO3, NaHCO3 and CHCl3 were purchased from Sigma Aldrich.  
Cell culture: 
Human bronchial epithelial cells A549 and H1299 were grown on 10 cm cell 
culture plates in DMEM medium containing 10% fetal bovine serum (FBS), 50 U 
mL-1 penicillin, 50 µg mL-1 streptomycin Fisher Scientific, Waltham, MA, and 
0.2% unlabeled glucose till 80% confluent as described previously (35). 
Metabolites extraction: 
At the time of harvest, media was removed and collected using transfer pipette. 
The cell plates were washed with ice cold PBS for 3 times and PBS was 
removed as much as possible by vacuum aspiration after the final wash. Then 
the cells are quenched using 1ml acetonitrile stored at -20°C, following addition 
of 750μl nanopure water. The cells were harvested by being scraped off from the 
plate. The whole process was repeated, following the addition of 1ml CHCl3 to 
extract polar, non-polar, protein fractions in CH3CN: H2O: CHCl3 2:1.5:1 (71). 
Then 1/16 of the aqueous phase containing polar extracts was aliquoted and 
lyophilized for ECF derivatization. 
Experiment procedure: 
100ul Na2CO3/NaHCO3 pH9.0 buffer was added to polyamine standards or cell 
polar extract and followed by the addition of 10µl iBuCF. After vortexing for 30s, 
the sample was allowed to set at 37˚ C for 15min then extracted twice by 200 µl 
 37  
chloroform (94). The chloroform extracts were pooled and dried under vacuum 
centrifugation and redissolved in 500 µl acetonitrile. Then the samples were 
diluted in 90% acetonitrile and directly sprayed using nano-ESI for UHR-FTMS 
analysis.  
UHR-FTMS analysis: 
The Orbitrap Fusion is from Thermo Scientific and the Triversa Nanomate is from 
Advion. The Triversa Nanomate was operated at 1.5kV and 0.5 psi head 
pressure for positive mode. The maximum ion time for the automatic gain control 
(AGC) was set to 100ms as described previously (68). Five transients were 
added to produce a stored spectrum. Spectra were acquired for more than 5 min. 
2.4.2.3 Results and Discussion 
Test on polyamine standards: 
I tested iBuCF derivatization of putrescine, cacaverine, spermine, and spermidine 
standards with a modified method from a literature (93). All of these four 
polyamines appeared to be be fully derivatized observed as Na adducts in UHR-
FTMS positive mode (Figure 2.11), so these forms were used for quantitative 
work described below.  
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Figure 2.11 FTMS spectra of iBuCF derivatized polyamines.  
iBuCF can fully derivatize putrescine, cadaverine, spermine and spermidine. The 
derivatized products could be detected in UHR-FTMS as Na adducts in positive 
mode. 
Test on unlabeled cell polar extracts: 
Putrescine, spermine, and spermidine were detected in both A549 and H1299 
cell polar extracts with good intensities by direct-infusion UHR-FTMS (Figure 
2.12).  
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Figure 2.12 FTMS spectra of iBuCF derivatized polyamines.  
Fully iBuCF derivatized putrescine, spermine, and spermidine were detected in 
both A549 and H1299 cell polar extracts as Na adducts.  
Linear response test of iBuCF derivatization of polyamines in H1299 cell 
polar extract using standard addition: 
Six H1299 cell polar extract samples (each sample contains 1/64 of a 15 cm 
plate H1299 cell polar extract) were prepared and polyamines (putrescine, 
cadaverine, spermine, spermidine) were added at different amounts: 0, 0.05, 0.1, 
0.25, 0.5, 1 nmol to achieve a standard addition curve. Then the samples were 
derivatized with iBuCF. 
All the 4 polyamines showed very excellent linear response with R2 values >0.98. 
Based on the standard addition equations, I can further calculate the original 
concentration of each polyamine present in cell polar extract. The good linear 
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response of the iBuCF derivatization method using direct infusion enables the 
absolute quantification of polyamines in bio-samples. 
 
Figure 2.13 Linear response results of the iBuCF derivatizaion of 
polyamines in H1299 cell polar extract using standard addition. 
All polyamines were fully derivatized and detected as Na adducts in UHR-FTMS. 
N=3. 
 
2.5 Conclusion 
I have developed and modified the rapid ECF and iBuCF derivatization methods 
for amino and carboxyl group containing metabolites, suitable for UHR-FTMS 
coupled with nano-ESI analysis. For ECF derivatization, with the chloroformate 
extraction, the salt contained in the polar bio samples was eliminated, which 
avoids major ion suppression effect in the polar samples. Diluting and injecting 
the samples directly after derivatization avoids additional issues not discussed 
above, such as the volatility of the derivatized products, which can otherwise lead 
to variable quantification. With the direct infusion, we were able to detect ECF 
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derivatized arginine, which was not amenable by GCMS previously. Spiking of 
uniformly 15N labeled amino acids as internal standards can normalize any effect 
from the derivatization efficiency, the sample stability, or sample loss during the 
experiment.  For the iBuCF derivatization, good linear response of the 
polyamines in cell culture extract samples with the standard addition method has 
been demonstrated. Further study could be conducted by designing stable 
isotope tracer experiments with the labeled polyamine precursors arginine and 
ornithine to profile the polyamine metabolism. With the stable isotope labeling of 
precursors and UHR-FTMS, we can unprecedentedly trace multiple isotope 
atoms in biological model systems with high accuracy, further opening the door 
for versatile, multi-isotope SIRM studies. 
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Chapter 3 : Metabolic reprogramming in lung cancer cell lines versus non-
cancer lung cells and human lung cancer tissue versus non-cancer tissue 
slices   
3.1 Introduction 
To explore how the metabolism is reprogrammed in lung cancer cells compared 
with non-cancer cells, and how the reprogramming differs among various lung 
cancer cell lines, we used the stable isotope labeling approach, in combination 
with the developed methods previously described, to characterize the metabolic 
alterations by UHR-FTMS.  
Glycolysis and the Krebs Cycle are among the central pathways which provide 
essential metabolic substrates and energy for cell growth and survival. Several 
amino acids are products of these pathways. Ala can be de novo synthesized 
from pyruvate, which can be generated from glucose though glycolysis, by 
accepting the amino group from Glu through alanine aminotransferase (Figure 
3.1). Ser and Gly can be synthesized from 3-phosphoglucerate, which is also a 
glycolytic intermediate. Asp and Glu could be synthesized from oxaloacetate 
(OAA) and alpha-ketoglutarate, which are intermediate metabolites in the Krebs 
Cycle, by aspartate aminotransferase and glutamate dehydrogenase. Also, Pro 
can be synthesized from Glu through glutamate gamma-semialdehyde 
dehydrogenase (52).  
Besides glycolysis and the Krebs Cycle, Gly, Ser, Asp, and Gln are also essential 
precursors for nucleotide synthesis. The Gly-Ser exchange pathway also serves 
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as part of the one-carbon metabolism pathway, which is related to many carbon 
transfer reactions. Last but not least, as the building blocks of protein, amino 
acids metabolism analysis is crucial for protein metabolism study. Thus these 
nutritionally “non-essential” amino acids are actually essential for cell 
maintenance and proliferation, and tracing their metabolism reveals key 
metabolic pathway information regarding metabolic reprogramming in cancers. 
 
Figure 3.1 Amino acids are involved in several central metabolic pathways 
(not all pathway involved are shown). 
G6P: glucose 6-phosphate, F6P: fructose 6-phosphate, fructose-1,6-bisP: 
fructose-1,6-bisphosphate, DHAP: dihydroxyacetone phosphate, G3P: glycerol 3-
phosphate, GAP: glyceraldehyde 3-phosphate, 3PG: 3-phosphoglycerate, OAA: 
oxaloacetate, α-KG: α-ketoglutarate, PPP: pentose phosphate pathway. 
The use of stable isotope resolved metabolomics (SIRM) has been well 
established among cell lines (34, 38, 43, 95). Lipid biosynthesis has been studied 
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by UHR-FTMS and NMR through 13C isotopomer analysis (37). Nucleotides and 
RNA metabolism is also well characterized using SIRM (36, 68). This study aims 
to elucidate selected aspects of detailed amino acids metabolism, using the 
combination of methods developed as described previously, to further uncover 
what and how other metabolism pathways altered in cancer cells or tissues. 
 
3.2 Methods 
Preparation of 13C6-Glc labeled cell polar extract 
Immortalized human bronchial epithelial BEAS-2B cells, human alveolar basal 
epithelial A549 adenocarcinoma cell and human lung adenocarcinoma PC-9 cells 
were grown on 10 cm cell culture plates in DMEM medium containing 10% fetal 
bovine serum (FBS), 50 U mL-1 penicillin, 50 µg mL-1 streptomycin (Fisher 
Scientific, Waltham, MA), and 0.2% unlabeled glucose for two days first. Then 
the media was changed to DMEM media (Life Technologies, Carlsbad, CA) 
containing 10% dialyzed fetal bovine serum, 50 U mL-1 penicillin, 50 µg mL-1 
streptomycin (Fisher Scientific, Waltham, MA), 2 mM Gln, and also with 0.45% 
13C6-Glc, 0.4 mM unlabeled Ser, and 0.4 mM unlabeled Gly. After 24 h, the cells 
were quenched, harvested, and extracted with CH3CN: H2O: CHCl3 (2:1.5:1) 
(71). Then 1/16 of the aqueous phase containing polar extracts was aliquoted 
and lyophilized for ECF derivatization. 
 
Preparation of double tracer labeled PC-9 cell polar extract 
 45  
Human lung adenocarcinoma PC-9 cells were grown on 10 cm cell culture plates 
in DMEM medium containing 10% FBS, 50 U mL-1 penicillin, 50 µg mL-1 
streptomycin (Fisher Scientific, Waltham, MA), and 0.2% unlabeled glucose for 
two days first. Then the media was changed to DMEM media (Life Technologies, 
Carlsbad, CA) containing 10% dialyzed fetal bovine serum, 50 U mL-1 penicillin, 
50 µg mL-1 streptomycin (Fisher Scientific, Waltham, MA), 2 mM Gln, and also 
with 0.45% 13C6-Glc/0.4 mM unlabeled Ser/0.4 mM unlabeled Gly, or 0.45% 13C6-
Glc/0.4 mM 2H3-Ser (or D3-Ser) /0.4 mM unlabeled Gly, or 0.45% 13C6-Glc/0.4 
mM unlabeled Ser/0.4 mM 2H2-Gly (or D2-Gly) respectively for different isotope 
tracer groups. After 24 h, the cells were quenched, harvested and extracted with 
CH3CN: H2O: CHCl3 (2:1.5:1) as described in (71). Then 1/16 of the aqueous 
phase containing polar extracts was aliquoted and freeze dried for ECF 
derivatization. 
Preparation of lung cancer patient tissue polar extract: 
Human cancer tissues and surrounding non-cancer tissues were collected in the 
operating room within 5 minutes of resection from patients under our University 
of Kentucky IRB protocol (IRB 14-0288-F6A). The surgeon cut the tissue into thin 
slices at approximately 0.7 to 1 mm thickness. These paired cancer and non-
cancer tissue slices were collected within minutes of surgical resection and 
incubated in glucose-free, Gly-free, and Ser-free DMEM medium (Life 
Technologies, Carlsbad, CA) with 10% dialyzed fetal bovine serum, 50 U mL-1 
penicillin, 50 µg mL-1 streptomycin (Fisher Scientific, Waltham, MA), 2 mM Gln, 
0.4 mM Ser, 0.4 mM Gly and 0.45% 13C6-Glc. The slices were cultured at 37 °C 
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with 5% CO2 for 24 h with gentle rotating as described (96). Then the slices were 
quickly rinsed in cold PBS 3 times to remove any remaining media, vacuum 
aspirated, and then flash frozen in liquid N2. The frozen tissue slices were then 
homogenized in 60% cold CH3CN in a ball mill (Precellys-24, Bertin 
Technologies, Washington, DC, MD), then extracted with CH3CN:H2O:CHCl3 
(2:1.5:1) (71). Again 1/16 of the aqueous phase containing polar extracts was 
aliquoted and lyophilized for ECF derivatization. 
Preparation of the hydrolysis of protein from lung cancer patient  
After polar and lipid extraction of the ground tissue sample, the protein pellet was 
dried in a vacuum centrifuge and then extracted with 62.5 mM Tris with 2% SDS, 
1mM dithiothreitol (DTT) (71). The protein solution was precipitated again with 
10% TCA, washed with water for twice. Then the protein pellet was hydrolyzed in 
6 M HCl with a focused beam microwave CEM at 160 °C for 10 min. Then 
hydrolyzed samples were aliquoted and freeze-dried for ECF derivatization. 
ECF derivatization: 
For the amino acid standard, 9 µL of amino acid standard samples were taken at 
the concentration above. For the cell/tissue/plasma polar extract, the freeze-dried 
FTMS fraction was used directly. H2O/Ethanol/Pyridine (6:3:1) mixture 100 µL 
was added, followed by 5 µL ECF. The mixture was vortexed and allowed to 
react for 30 s. 100 µL chloroform was then added to extract the products followed 
by 10 µL 7 M NaOH to adjust the aqueous layer to pH 9-10, after which a further 
5 µL of ECF was added and allowed to react again for 30 s. The solution was 
extracted a second time with 100 µL chloroform combined with the 1st time 
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extract. The chloroform extract was diluted 100-fold for the amino acid standards 
and 10-fold for cell or tissue samples with 90% acetonitrile plus 20 µM NaCl to 
convert the ions to the sodium adduct. The samples were then directly injected 
into the UHRFTMS using nano-ESI for analysis.   
Mass spectrometry and peak assignments 
UHR-FTMS was carried out using the Tribrid Fusion Orbitrap (Thermo Scientific), 
interfaced with a Triversa Nanomate (Advion). The Nanomate was operated at 
1.5 kV and 0.5 psi head pressure for positive mode. The maximum ion time for 
the automatic gain control (AGC) was set to 100 ms (68). Five transients were 
added to produce a stored spectrum. Each spectrum was acquired for >5 min.  
All 12C, 13C and D isotopologue peaks were assigned using “PREMISE” 
(PRecaculated Exact Mass Isotopologue Search Engine) (37) based on their 
accurate m/z values and the natural abundance contribution of each 
isotopologue was stripped using the method developed by Dr. Hunter Moseley 
(76). 
Statistical analysis 
All metabolite abundances were normalized by the extracted protein weight 
analyzed via the BCA method. The results were represented as the mean of 
metabolites from replicate samples. The error bars represent the standard error. 
The specific sample replicate numbers are stated in the figure legends. Based on 
our laboratory’s previous similar experimental data, the metabolites’ data 
measured from these kind of experiments is normal enough to use standard 
statistical procedures. For paired cancer/non-cancer tissue slices, two-tailed 
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student unpaired t-test was used to calculate p-values and the significance was 
assumed for p-values less than 0.05.  
 
3.3 Results and Discussion 
3.3.1 Glycolysis metabolism is altered in cancer cells and cancer tissues 
revealed by amino acids metabolism. 
The 13C6-Glc is transformed to 13C3-pyruvate through glycolysis, which then 
proceeds to 13C3-Ala through alanine aminotransferase. I measured the Ala level 
in the polar extract from BEAS-2B, A549, and PC9 cell lines. From the fractional 
enrichment data (Figure 3.2), we saw higher 13C3 labeled Ala in BEAS-2B and 
PC9 cells (about 60-80%) as compared to A549 cells (about 20%), indicating the 
possibility that higher glycolysis activity in BEAS-2B and PC9 cell lines, which 
needs further confirmation from the medium analysis and lactate analysis. Ser 
can also be synthesized from glycolysis intermediate 3-phosphoglycerate and in 
turn, Gly can be generated from Ser through serine hydroxymethyl transferase. 
Therefore, 13C3 labeled Ser and 13C2 labeled Gly could also be generated from 
13C6-Glc. Both 13C3-Ser and 13C2-Gly were observed in polar extracts of BEAS-2B 
and PC9 cells; however, they were very low, at the detection limits, in the A549 
cell polar extract. We could also see 13C1- and 13C2-labeled Ser in BEAS-2B and 
PC9 cell lines and the pathway involved will be discussed in detail in section 
3.3.3. 
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Figure 3.2 Isotopologues of Ala, Ser, Gly analyzed by UHR-FTMS in 13C6-Glc 
labeled BEAS-2B, A549, PC9 cell polar extract.  
The graphs on the left show the absolute quantification of the metabolites in cell 
extract whereas the graphs on the right show the fractional enrichment, which 
could clearly represent the percentage of each isotopologues generated from 
different pathways. N=3. Error bars represent the standard error of mean (SEM). 
 
Similarly, I measured the isotopologues of these amino acids in the 13C6-Glc 
labeled polar extract of both cancer and non-cancer tissues slices experiment 
from lung cancer patients as shown in Figures 3.3 and 3.4. There was significant 
amount of 13C3-Ala synthesized in patient tissue slices after 24h incubation in 
13C6-Glc contained media. Compared with non-cancer slices, the 13C3-Ala is 
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synthesized much more in the cancerous tissue slices, which clearly indicates 
elevated activity of glycolysis in cancer tissues. Interestingly, 13C2-Gly and 13C3-
Ser were barely detectable in the polar extract in any of these patients, indicating 
either poor synthesis of these amino acids due to low activity of 
phosphoglycerate dehydrogenase/phosphoserine transaminase/phosphoserine 
phosphatase (PHGDH/PSAT/PSPH), or they are not freely present in the cell 
cytosol, or they are rapidly utilized such that the steady state pool is very low. 
This phenomenon is similar to what is observed in the A549 cell line. 
 
Figure 3.3 Isotopologues of Ala, Ser, Gly analyzed by UHR-FTMS in 13C6-Glc 
labeled UK018 slice polar extract.  
About 60% Ala is with 13C3 labeled in cancer lung slices after 24h incubation in 
13C6-Glc containing media comparing with only about 15% 13C3-Ala in non-
cancer slices, which is clearly indicating higher glycolysis activity in cancer lung 
slices. However, no 13C labeled Gly or Ser is observed in the polar extract of 
either cancer or non-cancer slices. N=2. Error bars represent SEM. 
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Figure 3.4 Isotopologues of Ala, Ser, Gly analyzed by UHR-FTMS in 13C6-Glc 
labeled UK022 slice polar extract. 
About 80% Ala is with 13C3 labeled in cancer lung slices after 24h incubation in 
13C6-Glc containing media comparing with only about 30% 13C3-Ala in non-
cancer slices, which is clearly indicating higher glycolysis activity in cancer lung 
slices. However, no 13C labeled Gly or Ser is observed in the polar extract of 
either cancer or non-cancer slices. N=3. Error bars represent SEM. 
 
3.3.2 The activity of the Krebs cycle and pyruvate carboxylase (PCB) is 
altered in lung cancer cells and tissues. 
I also quantified the Asp and Glu in these cell lines and tissue extracts. Both Asp 
and Glu can be synthesized from the intermediates of the Krebs Cycle, 
oxaloacetate (OAA) and α-ketoglutarate. Therefore, the labeling level of these 
amino acids from 13C6–Glc is an indicator for the activity of the Krebs Cycle.  
As shown in Figure 3.5 (A), the 13C6-Glc is metabolized to 13C2-acetyl-CoA 
through glycolysis and pyruvate dehydrogenase (PDH), as shown by red colored 
dots. The 13C2-acetyl-CoA can then condense with unlabeled OAA to form 13C2 
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labeled citrate. The 13C2 labeled citrate then undergoes decarboxylation to form 
13C2 labeled α-ketoglutarate, which can convert to 13C2 glutamate labeled at the 
C4,5 position. The α-ketoglutarate can be further decarboxylated to form 13C2 
succinate. Since succinate has a symmetric structure, both C1,2- or C3,4-labeled 
succinate could be formed at 50% chance (could not be structurally 
distinguished). These two 13C2 structures then goes through fumarate, malate, 
and OAA, also forming 13C2-labeled Asp, with equal possibility of being labeled at 
C1,2 or C3,4. Simultaneously, the 13C3-pyruvate can also enter into the Krebs 
Cycle through pyruvate carboxylase (PCB) (Figure 3.5 (B)), to form 13C3-labeled 
OAA, which can then generate 13C3-labeled Asp, and the Glu formed from the 
PCB pathway in the first cycle of the Krebs Cycle will be labeled at the C2,3 
position. Therefore, studying the labeling patterns of Asp and Glu not only gives 
us the activity information of the Krebs Cycle, but also provides the enzyme 
activity information of PDH and PCB.  
Figure 3.6 shows the Asp and Glu data for the 13C5-Glc labeled BEAS-2B, A549 
and PC9 cell experiments. Asp, especially the fractional enrichment data, clearly 
shows that the BEAS-2B and PC9 cells have similar enrichment of Asp and the 
A549 cells have less. About 20% of Asp is doubly labeled and about 15% of Asp 
is triply labeled in BEAS-2B and PC9 cells whereas only 15% Asp is doubly 
labeled and 10% Asp is triply labeled in A549 cells. Except for 13C2-Glu, all other 
isotopologues of Glu, 13C1, 13C3, 13C4, and 13C5 could be generated from 
additional cycles of the Krebs Cycle. Although there were similarities among the 
three cell lines for Asp labeling, the enrichment in A549 cells appeared to be less 
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than the other two cell lines. All of these data indicates that the activity of the 
Krebs Cycle in A549 cells was lower than the other two cell lines in these 
particular experiments. 
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Figure 3.5 The 13C atom-resolved tracing of 13C6-Glc oxidation through the 
interconnecting cytoplasmic glycolysis and mitochondrial Krebs cycle is 
depicted.  
Panel A shows 13C incorporation from 13C6-Glc into various metabolites via the 
PDH pathway; panel B shows 13C incorporation from 13C6-Glc into metabolites 
via the PCB pathway. ●: 12C; ●: 13C; ●,● indicates 13C derived from PDH or PCB 
mediated Krebs cycle reactions, respectively; In panel A, the labeled patterns of 
the first and second (in brackets) turns of the PDH-initiated Krebs cycle are 
shown. In panel B, 13C3-pyruvate (Pyr) is carboxylated to form 13C3-oxaloacetate 
(OAA), leading to the formation of 13C3-Asp, -malate, -fumarate, and -succinate 
(patterns outside brackets); the labeled structures in brackets are derived from 
the reaction of 13C3-OAA with 13C2- or unlabeled acetyl CoA (AcCoA) to form 
other labeled Krebs cycle intermediates after one cycle turn. α-KG: α-
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ketoglutarate; PDH: pyruvate dehydrogenase; PCB: pyruvate carboxylase; not all 
expected labeled patterns of metabolites are shown (44). 
 
 
Figure 3.6 Isotopologues of Asp and Glu analyzed by UHR-FTMS in 13C6-Glc 
lableled BEAS-2B, A549, PC9 cell polar extract. 
The graphs on the left show the absolute quantification of the matabolites in cell 
extract whereas the graphs on the right show the fractional enrichment, which 
could clearly represent the percentage of each isotopologues generated from 
different pathways. N=3. Error bars represent the SEM. 
 
Turning now to patient tissue slices, I then measured Asp and Glu in paired 
cancer and non-cancer polar extracts as described above (Figure 3.7, 3.8). From 
the fractional enrichment data in all the patient  slices, the 13C3-Asp enrichment in 
cancer tissues appeared greater than in the non-cancer tissues. This is evidence 
that in human lung cancer tissues, the activity of PCB is elevated compared with 
non-cancerous tissues, consistent with findings directly from freeze-arrested 
tissue (38). After the 13C6-Glc enters glycolysis and the Krebs Cycle, 13C2-labeled 
α-ketoglutarate will be formed and, in turn, generates 13C2-labeled Glu through 
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glutamate dehydrogenase. In additional cycles of the Krebs Cycle, 13C3-, 13C4-, 
13C1-, and 13C5-α-ketoglutarate will be formed and thus generates 13C3-, 13C4-, 
13C1-, and 13C5-labeled Glu. From the fractional enrichment data, we can see that 
this activity is also upregulated in cancer tissue slices. 
 
  
Figure 3.7 Isotopologues of Asp and Glu analyzed by UHR-FTMS in 13C6-Glc 
labeled UK018 human tissueslice polar extract. 
Both 13C2 and 13C3 labeled Asp was found in the extract of tissue slices indicating 
the Asp was synthesized through PDH or PCB pathways. The 13C2-Glu is 
generated from first cycle of the Krebs Cycle from 13C6-Glc through 13C2-α-
ketoglutarate and glutamate dehydrogenase. 13C3, 13C4, 13C1 and 13C5 labeled 
Glu are generated from additional Krebs Cycles. N=2. Error bars represent SEM. 
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Figure 3.8 Isotopologues of Asp and Glu analyzed by UHR-FTMS in 13C6-Glc 
labeled UK022 human tissue slice polar extract. 
Both 13C2 and 13C3 labeled Asp was found in the extract of tissue slices indicating 
the Asp was synthesized through PDH or PCB pathways. The 13C2-Glu is 
generated from first cycle of the Krebs Cycle from 13C6-Glc through 13C2-α-
ketoglutarate and glutamate dehydrogenase. 13C3, 13C4, 13C1 and 13C5 labeled 
Glu is generated from additional Krebs Cycles. N=3. Error bars represent SEM. 
 
3.3.3 One-carbon metabolism pathway is altered in lung cancer cell lines 
and human lung cancer tissues. 
As indicated in Figure 3.9, Gly and Ser could be exchanged through serine 
hydroxyl methyl transferase (SHMT) with the facility of tetrahydrofolate (THF), 
which serves as part of the one-carbon metabolism. Using 2H to label exogenous 
(medium) Gly and Ser could differentiate them from unlabeled Gly and Ser 
derived from unlabeled sources such as protein turnover, and also from de novo 
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synthesized 13C-Gly and 13C-Ser. Also shown in Figure 3.9, there could be 
different pools of Ser or Gly in cell or tissue polar extract, either from the external 
media (red and green blocks) or through de novo synthesis (blue blocks). The 
13C or 2H (D) labeling patterns of Ser or Gly can indicate the sources of the Ser 
and Gly. 
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Figure 3.9 De novo synthesis of Ser and Gly from glucose via glycolysis 
and the 3-phosphoglycerate (3PG) pathway and exchanges of exogenously 
derived serine and glycine via one-carbon metabolism. 
Selected Ser and Gly exchange reactions are depicted for the cytoplasmic and 
mitochondrial compartments to illustrate the production of different 2H 
isotopologues of Gly and Ser. For example, the serine hydroxymethyl transferase 
(SHMT) reaction was shown for the cytoplasm (SHMT1) but omitted for the 
mitochondria (SHMT2) (44, 97). Blue text blocks track the de novo synthesis 
pathway from 13C6-glucose while green and beige text blocks respectively trace 
the exchange pathway of Gly and Ser via 1-carbon metabolism catalyzed by 
SHMT1, glycine decarboxylase complex (GLDC), and methylenetetrahydrofolate 
dehydrogenase (MTHFD). PHGDH: phosphoglycerate dehydrogenase; PSAT1: 
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phosphoserine amino transferase 1; MTHFD2: mitochondrial NAD+-dependent 
methylene tetrahydrofolate dehydrogenase/methylene tetrahydrofolate 
cyclohydrolase; MTHFD2L:  mitochondrial NADP+-dependent methylene 
tetrahydrofolate dehydrogenase.  
Culturing the A549 and PC9 cells and human lung tissues in simultaneous 13C6-
Glc, 2H2-Gly or simultaneous 13C6-Glc, 2H3-Ser containing media for 24 h, an 
interesting result was found as follows (Figure 3.10). In PC9 cells, levels of de 
novo synthesized Gly and Ser, i.e 13C2-Gly and 13C3-Ser were observed in the 
cell extract that was comparable to the level of 2H-labeled Gly and Ser, which 
came from external cultured media.  This showed metabolic synthesis of Gly and 
Ser from Glc simultaneous with uptake of external Gly and Ser.  However, in 
A549 cells, although the cells similarly contained 2H2-Gly and 2H3-Ser, almost no 
13C-labeled Gly or Ser was found. This phenomenon was mentioned before in 
the section 3.3.1. Additionally, for both PC9 and A549 cell experiments, not only 
the forms added to the media (2H2-Gly and 2H3-Ser) were detected, but also 2H1-
Gly, 2H1-Ser and 2H2-Ser were found in the polar extracts. This indicates active 
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Gly-Ser exchange metabolism present in these cell lines. 
 
Figure 3.10 Ser and Gly isotopologues in PC9 and A549 cell lines. 
In A549 cell polar extract, only external 2H labeled:  Gly or Ser in found. But in 
PC9 cell polar extract, both external 2H labeled:  and de novo synthesized 13C 
labeled:  Gly and Ser are found. Gly-Ser exchange reaction is active in both cell 
lines as 2H1, 2H2 labeled Gly and 2H1, 2H2, 2H3 labeled Ser are found in both cell 
lines. N=3. Error bars represent SEM. 
 
To determine if actual human lung cancers exhibit the same Ser and Gly 
behavior as the cells experiments, the same experiment was conducted on the 
lung cancer patients’ tissue slices (Figure 3.11, 3.12). Both cancer and non-
cancer tissues were cultured in 13C6-Glc only, 13C6-Glc plus 2H2-Gly, or 13C6-Glc 
plus 2H3-Ser media, each for 24h.  Indeed, similar to A549 cell lines, very little 
13C-labeled Gly or Ser was observed in the polar extract of any of the patients 
slices.  In contrast, both 2H-Gly and 2H-Ser forms were observed, with the uptake 
of Ser from media 2-3 times higher than Gly.  The distribution pattern of 2H-Gly 
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and 2H-Ser are different in cancer tissues versus non-cancer tissues. Specifically 
in non-cancer tissues, the “intact” 2H2-Gly or 2H3-Ser was at higher level whereas 
in cancer tissue, much less 2H2-Gly and 2H3-Ser was observed, but higher level 
of 2H1-Gly, 2H1-Ser and 2H2-Ser was present. This is evidence that the Gly-Ser 
exchange (Figure 3.9) activity is elevated in cancer tissues, indicating higher 
serine hydroxymethyl transferase (SHMT) activity.  
In summary, comparing human tissues with the cell lines, A549 was more similar 
to these specific human cancer tissues, as little Glc-derived 13C-labeled Gly or 
Ser could be observed in free cell or tissue polar extract. Also, the difference of 
the Ser-Gly-purine metabolism in cells and tissues might implicate the influence 
of tumor heterogeneity and/or microenvironment in human lung cancer tissues. 
This observation is valuable to guide researchers about the relevance cell 
models for cancer study. And such distinction in human cancer tissues compared 
with cell models will need to be considered in the development and testing of 
drugs.  
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Figure 3.11 Gly and Ser isotopologues from UK018 slice polar extract. 
Very little de novo synthesized Gly or Ser is observed in the polar extract. There 
is a significant amount of 2H-Gly and 2H-Ser taken up from external media. The 
Ser uptake is more than Gly, and the non-cancer tissue slices contain much 
more “intact” 2H2-Gly and 2H3-Ser, indicating higher Gly-Ser exchange activity in 
cancer tissues. N=3. Error bars represent SEM. 
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Figure 3.12 Gly and Ser isotopologues from UK022 slice polar extract.  
Very little de novo synthesized Gly or Ser is observed in polar extract. There is a 
fair amount of 2H-Gly and 2H-Ser taken up from external media. The Ser uptake 
is more than Gly, and the non-cancer tissue slices contain much more “intact” 
2H2-Gly and 2H3-Ser, indicating higher Gly-Ser exchange activity in cancer 
tissues. N=3. Error bars represent SEM. 
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The differences in the Ser and Gly isotopologues may be understood if we probe 
their downstream utilization. Gly and Ser are important bioprecursors of purine 
synthesis; Gly is both a direct and indirect precursor while Ser is a precursor in 
the sense that it makes Gly via SHMT (Figure 3.9 and 3.13).  In the purine ring 
structure, the atoms in blue and pink are derived from Gly or Ser. Therefore, by 
analyzing the labeling content of the purine rings, whether they are incorporated 
with 13C or 2H, we can discern if utilized Gly and/or Ser  comre from the external 
media, or from de novo synthesis through glycolysis from 13C6-Glc.  
Thus, we measured the nucleotides levels of these patient slice experiments 
using UHR-FTMS. (Figure 3.14) The result shows that there is a significant 
amount of 13C labeling in purine rings, indicating there is utliization of de novo 
synthesized Gly and Ser (from 13C-Glc) for purine synthesis, and therefore 
functional PHGDH/PSAT/PSPH activity.  However recall that these de novo 
synthesized Gly and Ser were barely present, which is consistent with low 
cytosolic levels in a free form, which could be the case if there is high efficiency 
at which these de novo synthesized Gly and Ser are utilized in purine synthesis. 
In contrast, very little deuterium is incorporated into purine ring from 2H2-Gly 
labeled media despite the high levels of it in the cells, but there is some 
deuterium incorporation into purine ring in the samples cultured in 2H3-Ser 
containing media, suggesting, as compared to Gly, Ser might actually be a 
prefered source of carbon in purine ring synthesis, although this potential 
preference is not shown in Figure 3.13.  Further, comparing the human cancer 
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tissue vs non-cancer tissues, there was more deuterium incorporation into the 
purine ring in non-cancer tissue. Such potential preferences of the de novo 
synthesized Ser and Gly from Glc for purine nucleotide synthesis may be keys to 
coupling substrate and energy supplies for the proliferation demand of cancer 
tissues. 
 
Figure 3.13 De novo synthesized Gly and Ser from 13C-Glc red dots 
represents the 13C:  and their incorporation into purine ring synthesis 
through THF. 
3-PG: 3-phosphoglycerate, PPP: pentose phosphate pathway, PRPP: 5-
phosphoribosyl 1-pyrophosphate 
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Figure 3.14 Purine ring labeling patterns of UK022 in tissue polar extract. D 
fraction represents the total fraction of deuterium labeled purine ring. 
More than 10 % of the carbons are 13C labeled in both cancer and non-cancer 
tissue. There is a fair amount of 2H incorporated into purine ring in the 2H-Ser 
labeled samples, but very little in the 2H-Gly labeled samples. More 2H is 
incorporated into purine in non-cancer tissue compared with cancer tissue. N=3. 
Error bars represent SEM. 
 
3.3.4 Protein turnover is altered in human lung cancer tissues. 
I also extracted the proteins from the tissue slices of the same patients described 
above. To determine the incorporation of labeled amino acids into the protein, I 
first hydrolyzed the protein by microwave digestion as described in the Methods 
(Ye et al unpublished method). Independent of the hydrolysis efficiency, the 
fractional enrichment data of the isotopologues of each amino acid is reliable. 
Figures 3.14 and 3.15 show the 13C fractional enrichments in amino acids 
released from the protein pool from the lung cancer patient (UK018 and UK022 
respectively) tissue slices extracts. While most of the amino acids were 
unlabeled in the protein, we observed significantly 13C-enriched Ala (about 5-
10%), which was elevated in the proteins from the cancer tissue than from the 
benign tissue. This indicates that the de novo synthesized amino acids are being 
incorporated into protein, and that the rate of protein synthesis is higher in the 
cancer than tin the non-cancerous tissue.  The enrichment of 13C in Asp is small 
(less than 1%), however, there is significant difference between the cancer and 
non-cancer tissues. Both 13C2- and 13C3-Asp were elevated in cancer tissue 
proteins, indicating increased activity of both PCB and PDH in cancer tissues. 
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We also see D-labeled Gly and Ser in the protein but hardly see any 13C-labeled 
Gly and Ser, which indicates the same possibility that the de novo synthesized 
serine and glycine from 13C6-glucose were consumed at very high efficiency for 
other purposes (e.g. nucleotides) rather than protein synthesis. Also, we see 
more scrambled Ser (D1, D2-Ser) and Gly (D1-Gly) in cancer slice proteins where 
as in non-cancer slice proteins it is less. This phenomenon is consistent with the 
tissue polar extract results. 
 
Figure 3.15 Isotopologues of amino acids hydrolyzed from protein of 
UK018. 
N=3. Error bars represent SEM. 
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Figure 3.16 Isotopologues of amino acids hydrolyzed from protein of 
UK022. 
N=3. Error bars represent SEM. 
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3.3.5 GSH metabolism is also altered in human lung cancer tissues. 
 
 
Figure 3.17 UHR-FTMS spectra of the isotopologues of ECF derivatized 
GSH.  
Both cancer tissue and non-cancer tissue from a same lung cancer patient 
(UK022) was tested. The y-axis represents the signal response of the UHR-
FTMS. X-axis represents the m/z of measured metabolites. The GSH 
isotopologue peaks are the ECF-derivatized, Na-adduct species.   
Still using the ECF derivatization method, I also measured the GSH level in 
patient tissue slices (UK022) with 13C6-Glc plus 2H-Gly medium. Both 13C-labeled 
and deuterium (D) labeled GSH could be observed. It seems a significant amount 
of external Gly (D-Gly) was used for GSH synthesis, especially in NC tissue 
slices. 
 
3.4 Conclusions 
The stable isotope labeling experiments enabled us to trace the labeled atoms 
from bioprecursors to different metabolites, thus allowing large amount of 
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detailed pathway information to be derived. In the previous studies of the polar 
metabolites in SIRM, GCMS was the long-standing tool for amino and carboxyl 
metabolites analysis with derivatization by MTBSTFA. However, due to several 
factors, including the limit of the resolution power of GCMS, dual tracer 
experiments are not fully characterizable by GCMS. However, with the methods I 
developed as described in Chapter 2, analyzing amino and carboxyl polar 
metabolites can be conducted rapidly and quantitatively using UHR-FTMS, 
enabling multi-tracer experiment analysis by mass spectrometry. This meant 
much more metabolic pathway information can be profiled at the same time, 
resulting in greater correspondence and comparison of the different isotopes, 
opening the possibility of involving different stable isotopes in precursors 
simultaneously, with multiple combinations of isotopic positions. 
I first used 13C6-Glc as a precursor in both different cell lines and in cancer and 
non-cancer tissue slices from NSCLC patients. Both glycolysis and the Krebs 
Cycles shows altered metabolic output in different lung cancer cell lines and 
human lung cancer tissue slices. 13C-labeled Ala was elevated in cancer tissue 
slices, which was expected based on the well-known fact that cancer cell 
undergoes higher anaerobic glycolysis than non-cancer cells in the Warburg 
effect. 13C-labeled Asp and Glu were also elevated, indicating elevated Krebs 
Cycle metabolism, which is controversial with the previous believe that the 
mitochondria was dysfunctional in cancer cells, but is consistent with recent 
findings using SIRM in our lab. Moreover, PCB activity is highly increased in 
 72  
cancer tissues as 13C3-Asp is significantly elevated in cancer tissues compared 
with non-cancer tissues. 
What is even more surprising is that 13C-labeled Gly and Ser were hardly found 
in A549 cells, with the same result NSCLC human tissue slices. The later 
nucleotide data showed that there was significant amount of 13C incorporation 
into purine ring biosynthesis, which at first seems to contradict the results. 
However, these findings taken together suggest that: 1) there is de novo 
synthesis of Gly and Ser in NSCLC tissue slices, both cancer and non-cancer; 2) 
after being de novo synthesized, Gly and Ser are utilized for other purposes at 
very high efficiency, resulting in small pools in the cytosol; and 3) purine ring 
synthesis is very likely to be one of the favored routes used for the de novo 
synthesized Gly and Ser went. Other than making Gly, Ser can also end up to 
make Cys, sphingosine, phospholipid head groups. Further studies on these 
metabolites could also help explain the fates of Ser. 
I further conducted dual tracer experiments 13C6-Glc/2H2-Gly and 13C6-Glc/2H3-
Ser on the cell lines and patient tissue slices. The Gly and Ser exchange 
reaction, as part of the one-carbon metabolism, was clearly detected as not only 
the intact form 2H2-Gly and 2H3-Ser were present, but also multiple patterns 2H1-
Gly, 2H1-Ser, 2H2-Ser were present. By comparing the cancer and non-cancer 
tissue slices, it seems that the Gly-Ser exchange reaction is more active in 
cancer tissues, based on the complex pattern, but in any case there was less 
externally imported (deuterated) forms of Gly and Ser present in cancer tissues 
as compared with non-cancer tissues. Moreover, the nucleotides data showed 
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that very little 2H-labeled Gly or Ser was incorporated into purine ring, especially 
in cancer tissues, further supporting that the nucleotide synthesis prefers de novo 
synthesized Gly and Ser. Also, Ser is more likely the preferred carbon source for 
purine ring synthesis than Gly. In summary, it seems that there are at least 3 
pools of Gly and Ser with distinct metabolic fates in human lung tissues. Pool 1 is 
the de novo synthesized Gly and Ser from glucose, which also served as the 
dominant substrate for purine synthesis in lung cancer tissues but less in non-
cancer tissues. Pool 2 is Gly and Ser is acquired from external source (2H-
labeled), which is more efficiently used in purine synthesis in non-cancer lung 
tissues compared to cancer tissues. And pool 3 is derived from other intracellular 
Ser and Gly sources (unlabeled) such as protein turnover.  
Therefore, protein turnover in NSCLC patient slices was studied by hydrolyzing it 
into single amino acids. Among all the amino acids, Ala showed the highest 
turnover rate up to ~10%. Similar to the tissue polar extract, de novo synthesized 
Asp through the Krebs cycle is incorporated into protein in cancer tissues at a 
higher relative level, and there was very little de novo synthesized Gly and Ser is 
used for protein synthesis. Also, the Gly and Ser had more mixed isotopic 
patterns in the protein of cancer tissues than in non-cancer tissues, possibly as a 
result of scrambling through a more active one-carbon pathway. 
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Chapter 4 : Metabolic changes in response to chronic exposure BEAS-2B 
cells to arsenite 
 
4.1 Introduction 
4.1.1 History and application 
Arsenic is a metalloid and occurs naturally in the Earth’s crust at 1.5 ppm. It is 
found in minerals, soil, and water in both inorganic or organic forms. The oxides 
and sulfides of arsenic have been known and used since ancient times. As early 
as the Bronze Age, arsenic was added to bronze to make the alloy harder (98, 
99), and had also been widely used as a pigment such as Paris Green or 
Scheele’s Green (100). As2O3 had been first used as therapeutic agent in ancient 
times to treat syphilis, tuberculosis, and skin disease (100). Since As2O3 is highly 
toxic, odorless, tasteless, and water-soluble, it became infamous as a lethal 
poison used for over 2000 years until the invention of the Marsh Test (101, 102). 
Until the 19th or early 20th century, arsenic was still widely used in agriculture 
because of its toxicity to insects, bacteria and fungi, as a wood preservative 
chromated copper arsenate (CCA), and as pesticides and rodenticides. Organic 
arsenic compounds were also used as feed additives like Roxarsone (100, 102-
104). However, these uses of arsenic are much less nowadays due to its well-
known toxicity. The use of CCA was banned by the European and by the United 
States in 2004 (105).  
Metallic As was applied in alloying mainly. For example, it was added to the lead 
component of car batteries to make the battery strengthened. In World War I, 
some arsenic-containing compounds were used as chemical weapons (106-109). 
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In the late 20th century, Chinese researchers investigated the medical use of 
arsenic trioxide to treat acute promyelocytic leukemia. And As2O3 arsenic trioxide 
was approved by US FDA in the year 2000 for chemotherapy treatment of 
patients with acute promyelocytic leukemia who are resistant to first line 
treatment with all-trans retinoic acid. 
4.1.2 Chronic exposure and toxicity 
The toxicity of chronic exposure to arsenic has increased in awareness. Arsenic 
can be absorbed and concentrated in plants, and then bio-accumulated through 
the food chain. The first report about the arsenic-related carcinoma of skin is by 
Hutchison in 1888 (110). Later investigators have shown strong association 
between arsenic and a variety of diseases and cancers (111). High arsenic 
levels, greater than the WHO’s standard of 10ppb in ground and drinking water 
has grown to be a big concern throughout the world (112). In the United States, 
arsenic has been found at high levels in ground water in the southwest part of the 
country, and millions of people live where there are high arsenic groundwater 
levels (113). In 2011, Joseph J. Putila published a strong association of arsenic 
exposure with lung cancer incidents in the USA (114). It was recently shown that 
arsenic-induced cellular transformation is coupled with changes in chromatin 
structure, transcriptome levels, and splicing patterns (115). Arsenic exposure 
may enhance the oxidative stress mediated RAS/ERK pathway and lead to cell 
proliferation (116),  and can also enhance  glycolysis, Gln metabolism, and 
nucleotide biosynthesis through activated HIF1-α (117). 
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Despite all these reports on the effect of arsenic-induced transformation, it is still 
unclear at the molecular level what specific aspects of the cellular metabolic 
networks are perturbed by arsenic, particularly arsenite, exposure. To address 
this issue, chronic toxicity of arsenite exposure to human bronchial epithelial 
BEAS-2B cells were studied in a long-period time course. BEAS-2B cells growing 
in different culture conditions were also studied and compared. SIRM was used 
as a main tool to profile the metabolic changes. 
 
4.2 Methods 
Cell culture (with the major help from Ms. Yang Zhang and Mr. Jeremy 
Johnson): 
Time course tracer experiment on the Immortalized human bronchial epithelial 
(BEAS-2B) cells with chronic NaAsO2 exposure: BEAS-2B cells were originally 
obtained from Dr. Xiangli Shi’s lab at the University of Kentucky. Then they were 
chronically exposed with 0.5 µM NaAsO2 continually over several months in Dr. 
Yvonne N Fondufe-Mittendorf‘s lab at the University of Kentucky. The exposed 
cells were obtained from Dr. Yvonne N Fondufe-Mittendorf’s lab weekly for the 
SIRM experiments performed by Yan Zhang. The BEAS-2B cells were cultured in 
DMEM medium plus 0.5µM NaAsO2, 10% fetal bovine serum (FBS), 50 U mL-1 
penicillin, 50 µg mL-1 streptomycin (Fisher Scientific, Waltham, MA), and 0.2% 
unlabeled glucose. After 24h, the media was changed to DMEM media (Life 
Technologies, Carlsbad, CA), containing 10% dialyzed fetal bovine serum, 50 U 
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mL-1 penicillin, 50 µg mL-1 streptomycin (Fisher Scientific, Waltham, MA), 2 mM 
Gln, 0.2% 13C6-Glc, and 0.5 µM NaAsO2. 
Another batch of immortalized human bronchial epithelial BEAS-2B cells were 
obtained from ATCC as a control and were grown on 10 cm cell culture plates in 
BEGM (Bronchial Epithelial Growth Medium) prepared from BEGM BulletKit (CC-
3170), Lonza. 
A third batch of BEAS-2B cells (a pair of control and 0.25 µM arsenite-treated 
cells for 6 months) was obtained from Dr. Fei Chen’s lab from Wayne State 
University (WSU). The cells treated with arsenite treatment have been shown to 
form metastatic tumors in mouse xenografts (118). The control and transformed 
cells were cultured in DMEM medium respectively without or with 0.25 µM  
NaAsO2, plus 10% fetal bovine serum (FBS), 50 U mL-1 penicillin, 50 µg mL-1 
streptomycin (Fisher Scientific, Waltham, MA), and 0.2% unlabeled glucose. 
After 24h, the media was changed to DMEM media (Life Technologies, Carlsbad, 
CA) containing 10% dialyzed fetal bovine serum, 50 U mL-1 penicillin, 50 µg mL-1 
streptomycin (Fisher Scientific, Waltham, MA) 2 mM Gln, and 0.2% 13C6-Glc, 
without or with 0.25 µM NaAsO2. 
In order to distinguish the As-treated and untreated BEAS-2B cells, we defined 
the NaAsO2 treated or transformed BEAS-2B cells as BAsT cells. 
Xenograft study: 
The mouse xenografts were performed by Dr. Ramon Sun. Both As-treated and 
untreated BEAS-2B cells (week 18) from Dr. Fondufe-Mittendorf‘s lab were 
injected into NOD/SCID/Gamma (NSG) mice through subcutaneous injection at 
10 million cells per 100µl, two injections per mouse at different subcutaneous 
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locations. After 16 weeks, when tumors were ready to harvest, the mice were fed 
with an in-house designed liquid diet in which 13C6-glucose was the primary 
carbohydrate source for 18 h as described previously. (Noninvasive liquid diet 
delivery of stable isotopes into PDX mice for deep metabolic pathway tracing 
Ramon C. Sun, Marc O. Warmoes, Ye Yang, Pan Deng, Qiushi Sun, Andrew N. 
Lane, Richard M. Higashi and Teresa W-M. Fan, Nature Communication, 2016 
(under review) The mice were then sacrificed and tumors were harvested. Then 
the tumors were flash frozen and ground in liquid N2.  
Metabolites extraction: 
For cell experiments: after 24 h, medium was removed and collected using a 
transfer pipette. The cell plates were washed with ice cold PBS for 3 times and 
PBS was removed as much as possible by vacuum aspiration after the last time 
wash. Then the cells were quenched using 1 ml acetonitrile (which was stored at 
-20°C), followed by the addition of 750 μl nanopure water. The cells were 
harvested by being scraped off of the plate. The whole process was repeated, 
then 1 ml CHCl3 was added to extract polar, non-polar, protein fractions in 
CH3CN: H2O: CHCl3 2:1.5:1 (71). Then 1/16 of the aqueous phase containing 
polar extracts was aliquoted and lyophilized for ECF derivatization. 
For tumor tissues: the ground tumor was quenched in 1ml 50% MeOH first. Then 
1.79 ml acetonitrile, 0.51 ml water, 0.2 ml 0.2mM Tris buffer and 1 ml CHCl3 were 
added for extraction of polar, non-polar and protein fractions. Again 1/16 of the 
aqueous phase containing polar extracts was aliquoted and freeze-dried for ECF 
derivatization. 
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ECF derivatization: 
For the amino acid standard, 9 µL of amino acid standard samples were taken at 
the concentration above. 100 µL of H2O/Ethanol/Pyridine (6:3:1) mixture and 5 
µL ECF were added to the cell polar extract. The mixture was vortexed and 
allowed to react for 30 s. 100 µL chloroform was then added to extract the 
products followed by 10 µL 7 M NaOH to adjust the aqueous layer to pH 9-10, 
after which a further 5 µL of ECF was added and allowed to react again for 30 s. 
The solution was extracted a second time with 100 µL chloroform combined with 
the 1st time extract. The chloroform extract was diluted 100-fold for the amino 
acid standards and 10-fold for cell or tissue samples with 90% acetonitrile plus 
20 µM NaCl to convert the ions to the sodium adduct. The samples were then 
directly injected into the UHR-FTMS using nano-ESI for analysis.   
Mass spectrometry and peak assignments 
UHR-FTMS was carried out using the Tribrid Fusion Orbitrap interfaced with an 
Advion Triversa Nanomate (Thermo Scientific).  The Triversa Nanomate was 
operated at 1.5 kV and 0.5 psi head pressure for positive mode. The maximum 
ion time for the automatic gain control (AGC) was set to 100 ms (68). Five 
transients were added to produce a stored spectrum. Each spectrum was 
acquired for >5 min.  
All 12C, 13C and D isotopologue peaks were assigned using “PREMISE” 
PRecaculated Exact Mass Isotopologue Search Engine (PREMESE) (37) based 
on their accurate m/z values and the natural abundance distribution of each 
isotopologue was stripped using the method developed by Moseley (76).  
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Statistical analysis 
All metabolite quantifications were normalized to the extracted protein weight 
determined via the BCA Protein Assay kit (Thermo Fisher Scientific). The results 
were presented as the mean and standard error of metabolites from replicate 
samples. The specific sample replicate numbers will be specified in the figure 
legend. In section 4.3.2.3, a two-tailed student unpaired t-test was used to 
calculate p-values and the significance was assumed for p-values less than 0.05.  
 
4.3 Results and Discussion 
4.3.1 Initial trial: 13C labeled time course experiments on 0.5 µM NaAsO2-
treated BEAS-2B cells: 
BAsT cells were continuously grown in 0.5 µM NaAsO2 containing DMEM 
medium in Dr. Yvonne N Fondufe-Mittendorf‘s lab. 13C6-Glc labeled experiments 
were conducted on the BAsT cells weekly and the cells were harvested and 
extracted for ECF derivatization. Figure 4.1 is the summary of the fractional 
enrichment of ECF-derivatized amino acids from week 1 to week 18. The results 
showed very high reproducibility over a long period. Significant 13C-labeled Ala, 
Gly, Asp, Ser, and Glu were found in all the samples. However, from the 
fractional enrichment data, during the 18-week exposure to 0.5 µM NaAsO2, no 
significant change was found in any of the metabolites I measured. The little 
change of the metabolic activity of these BAsT cells after long time exposure to 
NaAsO2 might be because the time of treatment is not long enough. 
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Figure 4.1 Fractional enrichment of isotopologues of amino acids analyzed 
by UHR-FTMS in 13C6-Glc lableled BAsT cells with 0.5μM As exposure at 
week 1 to week 18.  
No significant alteration was observed through week 1 to week 18 in any of these 
metabolites measured. N=3. Error bars represent SEM. 
 
A control group of BEAS-2B cell cultured in the same DMEM medium but without 
NaAsO2 treatment was also studied at week 15, 16, 17 and 18 using exactly the 
same methods. Figure 4.2 shows the comparison of the 13C label experimental 
results on BAsT cells and the control BEAS-2B cells at week 15 to 18. To our 
surprise, there was no difference of the labeling patterns in any of the 
metabolites measured, suggesting no significant metabolic change of these 
metabolites to the BEAS-2B cells during the 18-week exposure at 0.5µM 
NaAsO2.  
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Figure 4.2 Fractional enrichment of isotopologues of amino acids analyzed 
by UHR-FTMS in 13C6-Glc lableled BAsT cells with 0.5uM NaAsO2 exposure 
at week 15, 16, 17 and 18 and corresponding BEAS-2B control cells.  
No significant difference was observed in any of the metabolites measured. N=3. 
 
 
To investigate how these BEAS-2B and BAsT cells behave in vivo, a xenograft 
study was conducted on NOD/SCID/Gamma (NSG) mice through subcutaneous 
injection. After 16 weeks, to our surprise again, both BEAS-2B control group and 
the BAsT As-treated group formed tumors in mice. This fact questioned the “non-
tumorigenic nature” of the immortalized BEAS-2B cell lines. 
However, even both BEAS-2B and BAsT cause tumor generation in mice, the 13C 
fractional enrichment of metabolites extracted from the tumors showed significant 
difference between the BEAS-2B and the BAsT xenograft tumors. Figure 4.3 
shows the fractional enrichment of metabolites generated from 6 tumors from 4 
different mice. Two of the mice were injected with BEAS-2B cells and the other 
two with BAsT cells. The 13C3-Ala seems to be elevated in BAsT cell xenograft 
tumors, which indicated elevated glycolysis. 13C3-Asp enrichment in BAsT group 
was also significantly elevated, which was strong evidence that in BAsT 
xenograft tumors, the activity of PCB is elevated compared with BEAS-2B 
xenografts. After the 13C6-Glc enter glycolysis and the Krebs Cycle, 13C2-labeled 
α-ketoglutarate is formed and, in turn, generates 13C2-labeled Glu through 
glutamate dehydrogenase or transamination. In additional cycles of the Krebs 
Cycle, 13C3-, 13C4-, 13C1- and 13C5-α-ketoglutarate are formed and thus generates 
13C3-, 13C4-, 13C1-, and 13C5-labeled Glu. From the fractional enrichment data, we 
can see that these activities were also upregulated in BAsT xenograft tumors. 
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Gln had similar 13C labeling patterns as Glu due to exchange with each other 
though glutamine synthase and glutamate-aKG transaminase (GOT). The 13C 
incorporation into Gly and Ser was not as obvious as the other metabolites. 
However, we could still see that the 13C1- and 13C2-Ser was more abundant in 
BAsT xenografts, indicating that the Gly-Ser exchange activity was also elevated. 
Even both DMEM cultured BEAS-2B and BAsT cells caused tumor formation in 
mice; however, it seemed that the BAsT cells were “more” tumorgenic, given the 
fact that glycolysis, TCA cycle, and one carbon metabolism pathways were all 
elevated in the BAsT xenografts and the tumor weights were somewhat higher 
with BAsT than control cell xenografts. 
The unexpected inconsistency of the results from the cell lines and xenograft 
experiments might be explained as the maintained 3D structure and 
microenvironment of tumor is crucial for the transformed cells to have profound 
changes in the downstream metabolism. However, these could not explain why 
the BEAS-2B cells cultured in nominally control DMEM medium were also 
transformed. 
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Figure 4.3 Fractional enrichment of isotopologues of amino acids in 
xenograft tumor extract.  
The metabolism of tumor generated from BAsT cells and BEAS-2B cells showed 
difference in xenograft experiments.  
 
4.3.2 Further study: impact of different culture condition to BEAS-2B/BAsT 
metabolism. 
4.3.2.1 Cell morphology is altered in different culturing medium. 
Recent reports discussed the impact of culturing media to the phenotypes of 
BEAS-2B cells (119). In order to further test the impact of different culture media 
to the metabolism of these cells, 13C tracer experiments were conducted on the 
following cell lines: BEAS-2B cells cultured in BEGM media were obtained from 
ATCC; BEAS-2B and BAsT cells cultured in none or 0.25 μM added NaAsO2 
DMEM media were obtained from Wayne State University; BEAS-2B and BAsT 
cells cultured in none or 1 μM added NaAsO2 DMEM media were obtained from 
Dr. Xianglin Shi, University of Kentucky. The cell culture work was conducted 
mostly by Yan Zhang and Jeremy Johnson. Figure 4.4 shows the morphological 
change in two different media at different passage number (the cell pictures were 
taken by Yan Zhang). The BEAS-2B cells cultured in DMEM were as almost 
twice as big as the cells cultured in BEGM media according to ImageJ. And the 
cells grew bigger with higher passage number and in higher NaAsO2 
concentration medium. However there was no obvious difference between the 
NaAsO2-treated or untreated group. 
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Figure 4.4 Morphology compare of BEAS-2B cells cultured in different 
media.  
Cells cultured in DMEM medium grew larger than the cells cultured in BEGM 
medium. 
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4.3.2.2 As concentration test on plain DMEM and BEGM media. 
Considering that As is widely present in the environment, what is the As level in 
the plain cell culture medium? Is it possible that the impact of different culturing 
medium to BEAS-2B cells comes from the different As level? Also, considering 
the fact that BEAS-2B cells could cause tumor generation even without As 
treatment in previous xenograft experiments, it is crucially important to measure 
the As concentration in different plain medium.  
Figure 4.5 shows the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
measurement of As concentration in DMEM and BEGM medium. The ICP-MS 
measurement was conducted with the help of Teresa Cassel. Even in the plain 
medium, the total As concentration is approximately 0.2 μM, which is already 
close to the total As (as NaAsO2) concentration researchers use to chronically 
transform BEAS-2B cells (BAsT from WSU was cultured in 0.25 μM NaAsO2).  
Although, at this time, the chemical species of the total As background is 
unknown, some portion of this could be arsenite, and could explain why the 
control group BEAS-2B cells which were “never exposed” to As can also cause 
tumor generation. 
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Figure 4.5 ICP-MS measurement of As concentration in plain DMEM and 
BEGM medium. 
The ICP-MS result showed there was about 0.2 μM As present in both DMEM 
and BEGM medium. 
 
On the other hand, both DMEM and BEGM medium also had similar level of total 
As. Therefore, the total As level alone cannot be the major factor that causes 
cells to behave differently in different culturing medium. 
4.3.2.3 Culture conditions and As exposure impact metabolism in BEAS-2B 
cells. 
Figure 4.6 shows the 13C fractional enrichments of metabolites in different cell 
lines. First, comparing NaAsO2-treated or untreated BEAS-2B cultured in DMEM 
from UKY or WSU, no obvious trend of the metabolic change was observed in 
the metabolites I measured. This result is consistent with the previous 18-week 
time course experiment, in that the NaAsO2 chronic exposure did not give 
obvious changes in the metabolites I measured. Second, comparing DMEM-
cultured BEAS-2B and BAsT cells from different sources, which corresponds to 
different passage numbers and different cultured NaAsO2 concentrations, there 
were still no significant changes in the metabolites I measured. However, when I 
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compared the cells cultured in DMEM and BEGM (cell from ATCC) medium, it 
became clear that: (1) glycolysis in BEAS-2B/BAsT cells may be elevated in 
DMEM medium compared with BEGM, as shown by the level of 13C3-Ala, 13C3-
Ser and 13C2-Gly are all up regulated in DMEM medium. As mentioned before, 
13C6-Glc generates 13C3-pyruvate via glycolysis, and thus 13C3-Ala via the action 
of alanine aminotransferase. Ser can also be synthesized from the glycolytic 
intermediate 3-phosphoglycerate, and Gly could in turn be produced from Ser 
through serine hydroxymethyl transferase. Therefore, 13C3-Ala, 13C3-Ser and 
13C2-Gly can all serve as the indicators of activities of glycolytic enzymes. (2) 
PDH activity is maintained about the same while PCB activity is elevated in 
the DMEM cultured cells. This is indicated by the fractional enrichment of 13C2-
Asp, which is similar in different media but the level of 13C3-Asp is higher in 
DMEM cultured BEAS-2B cells. Again, as discussed before, when pyruvate 
generated from 13C6-Glc through glycolysis enters the Krebs cycle, both 13C2-Asp 
and13C3-Asp could be formed through PDH pathway or PCB pathway, 
respectively. Therefore, 13C2-Asp and 13C3-Asp could serve as indicators of the 
activities of PDH and PCB. (3) Ser-Gly exchange is up regulated in DMEM 
cultured BEAS-2B/BAsT cells, considering that more 13C1-Ser and 13C2-Ser are 
present in DMEM cultured cells. Ser-Gly exchange through THF can generate 
important carbon units for nucleotide synthesis, and this activity serves as one of 
the crucial parts of one-carbon metabolism. The multiple patterns of 13C-labeled 
Ser are important indicators of the Ser-Gly exchange pathway. (4) N-acetyl-
aspartate (N-AA) synthesis is up regulated. Recent studies have reported that 
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the role of increased N-AA in cancer (78, 79). It was surprising to see the sharp 
difference in the N-AA metabolism when BEAS-2B cells were cultured in DMEM 
versus BEGM medium. Much higher levels of de-novo synthesized N-AA (13C 
labeled) was observed in BEAS-2B cells cultured in DMEM than BEGM medium. 
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Figure 4.6 Fractional enrichment of metabolite isotopologues in 13C6-Glc 
lableled BEAS-2B/BAsT cells cultured in different condition.  
BEAS-2B/BAsT cells (p48) from UK were cultured in DMEM medium. NaAsO2 
concentration used for BAsT cell treatment was 1μM. BEAS-2B/BAsT cells (p16) 
from WSU were cultured in DMEM medium. NaAsO2 concentration used for 
BAsT cell treatment was 0.25μM. BEAS-2B cells (p13) from ATCC were cultured 
in BEGM medium. N=2. Error bars represent SEM. Group BAsT_WSU and 
BEAS2B_ATCC were compared as an example and calculated for p values. 
 
4.4. Conclusions 
To investigate cell metabolism may be interrupted by NaAsO2, an initial trial time 
course experiment on the BEAS-2B cells with chronic NaAsO2 exposure was 
conducted. However, after 18 weeks of exposure to 0.5 μM NaAsO2 
supplemented DMEM medium, the BAsT cells did not show significant metabolic 
change as measured by the ECF derivatization method. Also, no metabolic 
difference was observed compared with DMEM cultured BEAS-2B control cells. It 
was unexpected that both BEAS-2B control cells and BAsT cells caused tumor 
generation in the mouse xenograft experiments. Therefore, the “non-tumorigenic 
immortalized” BEAS-2B cells were actually “tumorigenic” when cultured in DMEM 
medium. Also surprising was that there were profound metabolic differences 
between the BEAS-2B and BAsT derived tumors. 
In addition, in order to study the impact of different culture conditions on BEAS-
2B cell metabolism, the As concentration was measured in plain DMEM and 
BEGM medium. An experiment-confounding level of total As was found in both 
media (0.2 μM), which might explain why the BEAS-2B control cells were also 
transformed to grow tumor in mice. An IC50 test was also conducted by Yan 
Zhang to determine to what extent the background As level (as NaAsO2) affected 
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the BEAS-2B in different medium. It turned out that the BEAS-2B cells cultured in 
DMEM medium (IC50 1.13 μM) was much more sensitive to NaAsO2 than the 
cells cultured in BEGM medium (IC50 6.83 μM) in a 72 h experiment. 
Finally, when BEAS-2B/BAsT cells cultured in different medium were compared. 
There was no significant difference between the NaAsO2-transformed or control 
groups, but significant metabolic difference was found in BEAS-2B cells cultured 
in DMEM versus BEGM medium. It is possible that background levels of total As 
interact with FBS to impact BEAS-2B cell metabolism and transformation since 
FBS exposure led to 43% overlap of gene expression changes (including 
carcinogenesis and energy metabolism pathways) as arsenite (119). 
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Chapter 5: Summary and Conclusions 
 
The goal of this dissertation is to determine how metabolism is altered in lung 
cancer cells and human lung tissues as compared with non-cancer cells and 
corresponding non-cancer paired tissues. Also, a comprehensive study of and 
how arsenite toxicity altered the metabolism in lung cells was conducted. SIRM 
was used as the main tool to generate a comprehensive profile of metabolic 
alterations that exist in different lung cell lines and in cancer or non-cancer lung 
tissues from the lung cancer patients. Amino and carboxyl small polar 
metabolites analysis by direct infusion UHR-FTMS, which serves as a key 
analytical tools for SIRM, has been difficult to achieve, although this task is 
crucially meaningful and important for fully mapping metabolic pathways.  
Therefore, first I developed methods to enable isotopologue analysis using the 
direct infusion high resolution FTMS, including the Z-tip ion-pairing method and 
the ECF and iBuCF derivatization methods. These methods enabled the UHR-
FTMS analysis of stable isotope labeled small polar metabolites with rapid 
analysis and with very good quantification ability. Furthermore, I developed a 
technique for analyzing the incorporation of stable isotope-enriched amino acids 
into proteins. I then applied these techniques to lung cancer metabolism. 
With the ECF derivatization of the polar metabolites, several pathways were 
examined simultaneously using SIRM experimental design. The iBuCF 
derivatization was successfully tested for detecting polyamines from the cell polar 
extract with good linear response. Further SIRM could be conducted to study the 
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polyamine related pathways with the stable isotope labeling of the bioprecursors 
of the polyamines like Arg and Ornithine.  
Glycolysis activity derived from the Ala, Ser, Gly metabolic data was studied. 
Compared to A549 cell lines, the BEAS-2B and PC9 cell lines show elevated 
glycolysis. Despite there is about 25% of Ala with 13C3 labeled, which indicates 
an active glycolysis exists in A549 cells, the 13C incorporation into Gly or Ser is 
hard to measure. This indicates either low activity of PHGDH/PSAT/PSPH or an 
efficient consumption of the de novo synthesized Gly and Ser. Similarly in the 
patient tissue slices study, as compared to non-cancer tissues, the cancer tissue 
slices show elevated glycolysis from the Ala data but no 13C-labeled Gly or Ser in 
the free cellular amino acid pool at detectable levels. 
The Krebs Cycle activity could also be derived from the Asp and Glu metabolic 
data. Compared with A549 cells, both BEAS-2B and PC9 cells show higher 
Krebs cycle activity. From lung cancer patients’ tissue slice experiment, it is clear 
that the Krebs cycle activity is elevated in cancer tissues, giving the fact that 
more 13C incorporation fractions in cancer tissues. Comparing the labeling 
patters of Asp 13C2 and 13C3 species, it is also very clear that the PCB activity is 
much elevated in cancer tissues as compared with non-cancer tissues. 
In addition, the one-carbon metabolism was studied based on Gly and Ser data 
from dual tracer experiments. Gly and Ser exchange is constantly observed in 
both cell lines and patients’ lung tissues. Interestingly, the exchange activity is 
much more active in cancer tissues as compared with non-cancer tissue, given 
the observation that more intact form of 2H2-Gly and 2H3-Ser is present in non-
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cancer tissues and more scrambling patterns of Gly and Ser in cancer tissues, 
which indicates increased activity of SHMT. With the combination of the 
nucleotide data, the significant 13C incorporation into purine ring indicates that 
there is significant de novo synthesized Gly and Ser, since the 13C incorporated 
in purine rings can only come from either Gly or Ser through THF. This is 
evidence that there is de novo synthesized Gly and Ser, and appear to be used 
for nucleotide synthesis at very high efficiency. 
Moreover, protein synthesis untilization of amino acids was studied by 
hydrolyzing proteins into their constituent amino acids. Cancer and non-cancer 
tissues showed differences in Ala, Asp, Gly, Ser incorporation into protein with 
similar patterns as the polar extract.  GSH was also studied in the lung tissue 
extract from cancer patients; it seems more external Gly was used for GSH 
synthesis in non-cancer slices as compared with cancer slices. 
In summary, in order to meet the energy demand for accelerating proliferation, 
lung cancer cells exhibit higher glycolysis and TCA activity. In particular, PCB 
activity is increased in lung cancer. In addition, SHMT activity is also elevated in 
lung cancer tissues. And to better serve the high substrate and energy demand 
for proliferation, it seems that cancer cells has its own preferred source of 
substrates when multiple sources are present. For example, even with abundant 
Ser in the external medium, the de novo synthesized Ser is a preferred substrate 
for nucleotide synthesis in cancer cells and tissues.     
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Finally, to be able to find out how the cell metabolism is interrupted by outside 
toxicants like As, a time course study on the BEAS-2B cells with chronic As 
exposure was conducted using stable isotope tracer labeling. In the initial time 
course trial studies, after 18 weeks of exposure to 0.5 μM NaAsO2, the BAsT 
cells did not show significant metabolic difference. And also no metabolic 
difference was observed compared with DMEM cultured BEAS-2B control cells. 
What is surprising is that both BEAS-2B control cells and BAsT cells caused 
tumor generation in the following xenograft experiments. Therefore, the “non-
tumorigenic immortalized” BEAS-2B cells might actually be “tumorigenic”, at least 
in DMEM medium with our NOD/SCID/Gamma (NSG) mice model. More 
surprising results were found out in that there are profound metabolic differences 
between the BEAS-2B and BAsT derived tumors. These findings might suggest 
that the maintained 3D structure of tumor microenvironment is crucial for the 
transformed cells to have profound changes in the downstream metabolism. 
Furthermore, As concentration was measured in plain DMEM and BEGM 
medium and an experiment-confounding level of total As was found in both 
media (0.2 μM). This might explain why the BEAS-2B control cells were also 
transformed to grow into tumors in mice. An IC50 test was also conducted 
subsequently to see to what extent the background As level (as NaAsO2) might 
affect the BEAS-2B in different medium. It turned out that the BEAS-2B cells 
cultured in DMEM medium (IC50 1.13 μM) is much more sensitive to NaAsO2 
than the cells cultured in BEGM medium (IC50 6.83 μM) in a 72 h experiment. 
Therefore, total As, even if all of it were arsenite, may not be the major causative 
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factor that altered the BEAS-2B cells in DMEM (both medium has similar level of 
As), but the DMEM altered BEAS-2B cells became more sensitive to NaAsO2. 
Finally, the metabolites in BEAS-2B/BAsT cells cultured in different medium were 
studied. There is no significant difference between the NaAsO2-treated or 
untreated groups, however, a significant metabolic difference was found in cells 
cultured in different medium. It seems that the FBS contained DMEM medium will 
make the BEAS-2B cells more likely to be transformed. It is possible that 
background levels of As interact with FBS to impact BEAS-2B cell metabolism 
and transformation since FBS exposure led to 43% overlap of gene expression 
changes as arsenite (119). 
Future directions will include: 1) conducting the isotope tracer time course 
experiments on BEAS-2B and BAsT cells (ATCC) with a higher As concentration 
treatment in both DMEM and BEGM medium, to see whether metabolic changes 
could be observed at higher As concentration (close to IC50); and 2) testing if the 
control BEAS-2B cells cultured in BEGM medium from ATCC will form tumors or 
not, and to further confirm if DMEM medium will lead to tumorigenic 
transformation, xenograft experiments will be conducted using the ATCC BEAS-
2B cells cultured in both BEGM and DMEM medium. Furthermore, it would be 
interesting to figure out what particular components in the DMEM medium 
triggered the alteration of BEAS-2B cells.    
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Appendices 
 
List of abbreviations 
 
NSCLC: Non-small cell lung cancer  
SCLC: Small cell lung cancer  
SIRM: Stable Isotope Resolved Metabolism 
UHR-FTMS: Ultra High Resolution-Fourier Transform mass spectrometers 
Nano-ESI: 
MTBSTFA: N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide  
ECF: ethyl chloroformate  
Fmoc-Cl: 9-Fluorenylmethyl-chloroformate  
nano-ESI: nano-electrospray ionization  
PFAs: perfluorocarboxylic acids  
PFB: perfluorobutynoic acid 
PFP: perfluoropentanoic acid  
PFhexa: perfluorohexanoic acid  
PFH: perfluoroheptanoic acid  
PFO: perfluorooctanoic acid  
PFN: perfluorononanoic acid  
AGC: automatic gain control  
FBS: fetal bovine serum  
NAA: N-acetylaspartate 
SAMe: S-adenosyl methionine 
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iBuCF: Isobutyl chloroformate 
ODC: ornithine decarboxylase 
G6P: glucose 6-phosphate  
F6P: fructose 6-phosphate 
fructose-1,6-bisP: fructose-1,6-bisphosphate 
DHAP: dihydroxyacetone phosphate 
G3P: glycerol 3-phosphate 
GAP: glyceraldehyde 3-phosphate 
3PG: 3-phosphoglycerate 
OAA: oxaloacetate 
α-KG: α-ketoglutarate 
PPP: pentose phosphate pathway. 
α-KG: α-ketoglutarate 
PDH: pyruvate dehydrogenase 
PCB: pyruvate carboxylase;  
SHMT1: serine hydroxymethyl transferase 
GLDC: glycine decarboxylase complex 
MTHFD: methylenetetrahydrofolate dehydrogenase 
PHGDH: phosphoglycerate dehydrogenase 
PSAT1: phosphoserine amino transferase 1 
MTHFD2: mitochondrial NAD+-dependent methylene tetrahydrofolate 
dehydrogenase/ methylene tetrahydrofolate cyclohydrolase 
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MTHFD2L:  mitochondrial NADP+-dependent methylene tetrahydrofolate 
dehydrogenase. 
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